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ABBREVIATIONS AND DEFINITIONS 
 
Abbreviations 
CD canine distemper 
CDV canine distemper virus 
CNS  central nervous system 
CSF cerebrospinal fluid 
DNA deoxyribonucleic acid 
EELA National Veterinary and Food Research Institute 
EID egg infectious dose 
ELISA enzyme-linked immunosorbent assay  
Evira  Finnish Food Safety Authority 
F fusion (protein) 
H hemagglutinin (protein) 
HI herd immunity 
ID50 infectious dose for half (50%) of target population 
IF immunofluorescence 
IFA immunofluorescence assay 
IgG immunoglobulin of type G 
IgM immunoglobulin of type M 
L large (protein) 
LD50 lethal dose for half (50%) of target population 
M matrix (protein) 
ML modified live 
MLV modified live vaccine 
MS market share 
P phospho (protein) 
PI post infection 
R net or effective reproduction number 
R0 basic reproduction number 
RNA ribonucleic acid 
RT-PCR reverse transcriptase-polymerase chain reaction 
SD standard deviation 
TCID tissue culture infectious dose 
UTR untranslated region 
UV ultra violet (light) 
VELL State Veterinary Institute 
VERO African green monkey kidney epithelial (cells) 
VI virus isolation 
VN virus neutralisation (assay) or virus neutralising (antibodies or titre) 
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Definitions 
 
Basic reproduction number, R0, of an infection is the number of secondary 
cases a typical single infected case will cause in a population with no 
immunity to the disease in the absence of interventions to control the 
infection. The net or effective reproduction number, R, is R0 * PS , the 
proportion of susceptible individuals in the population (Anderson and May 
1991). 
 
Efficacy or performance of a vaccine is the ability of the vaccine to prevent 
the adverse effects of the infection to the vaccinated animal itself, or the 
ability to induce antibodies in the vaccinated animal that are transferred to 
the offspring, and so provide protection to the newborn animals. In veterinary 
medicine/vaccinology efficacy is demonstrated under controlled conditions by 
vaccination-challenge tests using the target animal species (Soulebot et al. 
1997). 
 
Herd immunity is here defined as the proportion of subjects with immunity in 
a given population (herd). The vaccine induced herd immunity depends upon 
vaccination coverage and efficacy of the vaccine (John and Samuel 2000).  
 
Herd effect is the reduction of infection or disease in the unimmunised 
segment as a result of immunising a proportion of the population (John and 
Samuel 2000). 
 
Immunogenicity is the ability of a vaccine to stimulate the immune system, 
as measured for example by the proportion of individuals that produce 
specific antibody or T cells, or the amount of antibody produced. 
 
Infectivity is a measure of the ability of the infectious agent to establish itself 
in the host. This term can be used qualitatively (e.g. low, medium or high), or 
quantitatively. Attempts to quantify infectivity normally involve the use of a 
statistic known as infectious dose 50 (ID50). This refers to the individual dose 
or numbers of the agent required to infect 50% of a specified population of 
susceptible animals under controlled environmental conditions. It often is 
expensive or not feasible to determine in vivo ID50 and the infectivity is 
expressed using the tissue culture ID50 (TCID50) as the dimension (Putt et al. 
1988). 
 
Pathogenicity is an epidemiological term used to describe the ability of an 
agent of known virulence to produce disease in a range of hosts under a 
range of environmental conditions (Putt et al. 1988). 
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Performance of a vaccine. See efficacy. 
 
Potency testing of a vaccine is done to guarantee that each vaccine batch 
has the intended effect. In live vaccines, potency can be estimated for 
example by the number of organisms present. Potency tests must be 
validated by demonstrating a correlation between the results of the test and 
the efficacy of the vaccine in the target animal (Soulebot et al. 1997).  
 
Vaccine coverage (%) is the proportion of the population that has been 
vaccinated. 
 
Vaccine take (%) is the proportion of the vaccinated population in which 
vaccination has elicited a specific immune response, for example production 
of specific antibodies. 
 
Virulence is a measure of the severity of the disease caused by the agent. 
In a strict sense it is a laboratory term, used to measure the varying ability of 
the agent to produce disease under controlled conditions. It is often 
quantified by a statistic known as lethal dose 50 (LD50). This refers to the 
individual dose or numbers of the agent required to kill 50% of a specified 
population of susceptible animals under controlled environmental conditions 
(Putt et al. 1988).  
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ABSTRACT 
 
Canine distemper (CD) is one of the longest-known infectious diseases of 
dogs and is still prevalent in many parts of the world. Vaccination combined 
with biosecurity measures is the most productive way to prevent and control 
infectious diseases. The beneficial effects of vaccination are realized not 
only on the individual but also on the population level, the latter in the form of 
herd immunity (HI). Control of CD among dogs relies heavily on vaccination, 
while in fur farms and zoos with several species or large numbers of CD-
susceptible animals in close contact, biosecurity measures in some cases 
offer the only available means for CD control. Modified live CD virus vaccines 
have been successfully used to control CD among farmed mink, and since 
no licensed vaccines for other species kept for fur exist, mink CD vaccines 
have also been used for foxes and raccoon dogs in CD emergency 
situations.  
 
CD vaccines for dogs (Canis familiaris) and mink (Mustela vison) were 
studied in experimental settings for their ability to induce virus-neutralising 
(VN) antibodies in target species. Mink vaccines were also assessed in silver 
foxes (Vulpes vulpes), blue foxes (Alopex lagopus) and raccoon dogs 
(Nyctereutes procyonoides). Purpose-bred beagle dogs were vaccinated 
twice with one of three CD vaccines: Candur® SHP, Canlan®-3 or Dohyvac®  
DA2P, and the levels of VN antibodies were determined at the time of 
vaccination and one month after the second vaccination. Fur animals were 
vaccinated once with Distemink®, Distem®-R-TC or vaccine 3 (which was not 
licensed in Finland) and the levels of VN antibodies were determined at 
vaccination and 2-4 times 1-4 months afterwards. Significant differences 
among vaccine groups were found both in the proportion of animals with 
measurable levels of VN antibodies and in the mean titres of antibodies.  
 
The levels of VN antibodies were also determined from a large field sample 
(n = 4 627) of vaccinated dogs. In addition to the three CD vaccines in the 
seroconversion study above, additional two vaccines, Duramune®-4 and 
Nobivac® DHP, had been used in the field. Each dog with a known 
vaccination history, date of birth, sex and breed was sampled once. Based 
on the overall geometric mean titre of the dogs vaccinated with a single 
vaccine brand, vaccines were divided into high-take (Candur®, Nobivac® and 
Duramune®) and low-take (Dohyvac® and Canlan®) groups. The vaccine 
groups differed significantly among dogs less than two years of age both in 
the proportion of dogs with detectable VN antibodies and in the mean titres. 
Both the number of vaccinations and age were associated with the titre and 
vaccine usage. To control for possible confounding factors, the comparison 
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of titres among vaccine usage groups was adjusted by classifying them 
according to the number of vaccinations (one to four) and the age group 
(less than one, one to two, or over two years old). The same division into 
low- and high-take vaccines was observed, irrespective of the number of 
vaccinations the dogs had received. The observations of this seroprevalence 
study regarding Candur® , Canlan® and Dohyvac® were consistent with the 
results of the seroconversion study.  
 
CD was reintroduced into Finland in 1990 after 16 years of absence. The 
disease remained at a low endemic level in 1990-1994, reached epidemic 
proportions in 1994-1995 and disappeared during 1995. The epidemic also 
involved vaccinated dogs. Among the virologically-confirmed cases the 
proportion of Dohyvac®-vaccinated dogs was higher than expected from the 
market shares on the assumption that all the vaccines had an equal take. As 
a result of this observation, Dohyvac® was withdrawn from and Nobivac® and 
Duramune® introduced to the market during 1995. A drastic redistribution of 
the market shares between the low-take and high-take vaccines took place, 
and this coincided with the decline and dying out of the outbreak. The 
observed occurrence pattern of CD from 1990-1996 was largely attributed to 
the changes in the level of HI, although the possible contribution of other 
factors, such as developments in the dog demographics, was also 
recognized. It was concluded that an HI above 75% is needed to keep CD in 
check, i.e., only sporadic cases of CD, at most, can occur. With the currently 
used vaccines an HI of 80% corresponds to a vaccine coverage of some 
94%.  
 
It was concluded that the development of vaccine-induced immunity is a 
multifactorial process depending on the properties of the vaccine, on the 
individual variation, age, species and other factors influencing the 
immunocompetence of the host. On the individual level the prevention of 
clinical signs is sufficient, but on the population level, halting the circulation 
of the virus is crucial for the definitive control of CD. The ultimate test and 
criterion for a vaccine is its contribution to herd immunity. Heterogeneity in 
the dog population contributes to the occurrence of CD. 
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1. INTRODUCTION 
 
 
For centuries, infections by morbilliviruses have imposed a significant burden 
on both human and animal populations. Measles, which was introduced by 
the Europeans to America, devastated the populations of native Americans. 
Rinderpest, a morbillivirus infection of cattle, was introduced to Europe by 
traders coming from Asia and later to Africa by colonial wars, and it severely 
affected both domestic and wildlife species. Measles still prevails as an 
important childhood disease, especially in the developing countries (WHO 
2007), but outbreaks also continue to occur in developed countries, when or 
wherever vaccine coverage wanes (Mossong and Muller 2000, van den Hof 
et al. 2001). Global eradication of rinderpest is underway, but peste des 
petits ruminants, a morbillivirus infection of sheep and goat, remains 
endemic in Africa and has spread to the Middle East and southern Asia 
(Shaila et al. 1996).  
 
Canine distemper, a morbillivirus infection of dogs and other carnivores, has 
been recognized for at least 250 years. As reviewed by Blancou (2004), the 
first report of canine distemper (CD) is from South America by Ulloa in 1746. 
Heusinger was convinced that CD was introduced in 1760 from Peru to 
Spain, from where it spread to other parts of Europe and Russia within a few 
years. Although CD may have occurred in Europe earlier and was possibly 
confused with rabies, the epidemic spread of CD through Europe started 
around the 1760s. In 1815 Jenner observed that CD among dogs is as 
contagious as smallpox, measles and scarlet fever among humans. He 
attempted vaccination against CD in the way found successful in vaccinating 
against smallpox. Karle succeeded in experimentally transmitting  CD in 
1844, by brushing the lips of young dogs with discharge from diseased dogs. 
The etiology of CD remained controversial until 1905, when Henri Carré 
demonstrated that CD is caused by a filterable virus. In some connections, 
CD is still called Carré’s disease.  
 
The first vaccine against CD was made in 1923 by Puntoni from the formalin-
inactivated brain tissue of a dog suffering from CD encephalitis (reviewed by 
Appel 1999). The protection obtained with inactivated vaccines was limited, 
and they are no longer used. The modified live (ML) vaccines by which CD 
can be successfully controlled were developed in the late 1950s. The CD 
viruses adapted to chicken embryonated eggs were named Lederle (Cox and 
Cabasso 1952) and Onderstepoort (Haig 1956) strains. A canine kidney cell 
culture adapted strain was named the Rockborn strain (Rockborn 1959).
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Although the use of ML vaccines has significantly reduced the incidence of 
CD, the circulation of CD virus in populations of dogs and other susceptible 
carnivores continues. This circulation manifests itself as the sporadic, 
endemic or epidemic occurrence of CD, and outbreaks of CD also involve 
vaccinated dogs (Glardon and Stöckli 1985, Adelus-Neveu et al. 1991, 
Blixenkrone-Møller et al. 1993). The neglecting of vaccinations, leading to 
poor vaccine coverage and herd immunity, is an obvious reason for 
outbreaks on the population level. Antigenic shift in the wild CD viruses, 
making the current vaccines unprotective, has been suggested as a cause, 
but never proven. On the individual level, interference by maternal 
antibodies, immunosuppression caused by concurrent infections such as 
canine parvovirus or a heavy load of internal parasites, and improper storage 
and handling of the vaccine have been blamed for vaccine failures (Povey 
1986, Tizard 2000, Greene and Appel 2006). However, the ultimate reason 
for the vaccine failures may lie in the inherent properties of the vaccines 
themselves. 
 
In the development of an ML vaccine, a balance must be reached between 
two opposing aims: safety and efficacy. On the individual level, vaccination 
can be considered to have succeeded when the vaccine itself has not 
induced disease and no signs of a disease are observed after challenge. 
However, on the population level, the circulation of a pathogen should be 
stopped. This is possible if vaccines that induce a sufficiently vigorous 
immune response to prevent the replication of a wild CDV, and not only the 
clinical signs, are used and a high enough vaccine coverage is maintained. 
Unfortunately, the current requirements for a vaccine to be accepted in the 
market are concentrated on the prevention of clinical disease after challenge 
(European Pharmacopoeia). The importance of field trials before accepting 
the vaccine in the market has only recently been recognized.  
 
Two seroconversion studies (I, II) were conducted in order to determine 
whether commercial CD and mink distemper vaccines differ in their take or in 
the level of antibodies induced by vaccination. The performance of the 
vaccines under field conditions according to the above-mentioned criteria 
was explored in a seroprevalence study (III). In a preliminary report (IV) the 
causes of the outbreak among vaccinated dogs were sought, and finally, an 
attempt was made to explain the observed pattern of CD occurrence in 
Finland from 1990-1996 by using vaccine coverage and herd immunity as 
explanatory factors (V). The level of herd immunity (%) that is critical for the 
control of CD in Finland was pinpointed and the vaccine coverage needed to 
sustain this level with currently available vaccines was suggested.
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2. REVIEW OF LITERATURE 
 
 
2.1 Canine distemper 
 
2.1.1 Etiology 
 
Canine distemper virus (CDV) belongs to the genus Morbillivirus in the 
Paramyxoviridae family. The type virus of the genus is measles virus. The 
morbilliviruses, the diseases that they cause and their natural hosts are 
presented in Table 1. Morbilliviruses consist of a non-segmented linear 
single-stranded RNA genome of negative polarity comprising about 15 900 
bp. The RNA is enclosed in a helical nucleocapsid formed by the N protein. 
In addition, mature ribonucleoprotein complexes also contain copies of the 
phospho- (P) and large (L) proteins. The host-cell-derived lipid envelope is 
spiked with transmembrane haemagglutinin (H) and fusion (F) glycoproteins. 
Internally, the envelope is stabilized by a layer of the matrix (M) protein 
(Figure 1). Genes in the genome are in the following order: 3’-UTR-N-P(C,V)-
M-UTR-F-H-L-UTR-5’. P gene encodes two non-structural proteins C and V 
in addition to P protein (Griffin, 2001).  
 
Table 1 Viruses belonging to the genus Morbillivirus and diseases that they cause in 
their natural hosts (modified from Osterhaus et al. 1995 and Di Guardo et al. 2005). 
 
 Virus Disease   Natural host   
 
Measles virus (MV) Measles  Human 
 
 
Rinderpest virus (RPV) Rinderpest  Cattle, goat, sheep, pig 
 
 
Peste des petits ruminants virus 
(PPRV) 
Peste des petits 
ruminants   Goat, sheep  
 Dolphin morbillivirus (DMV)   Dolphin  
 Porpoise morbillivirus (PMV)   Porpoise  
 
Canine distemper virus (CDV) Canine distemper  Dog  
 
Phocine distemper virus (PDV)    Seal 
  
 
DMV and PMV are currently gathered under the common denomination of 
'cetacean morbilliviruses' (CMV). 
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CDV is susceptible to visible and UV light and extremely susceptible to heat 
and drying. It is destroyed by temperatures above 50 oC in 30 minutes, but it 
can survive for 48 hours at +25 oC and for 14 days at + 5 oC (Shen and 
Gorham 1980). At near freezing temperatures (0–4oC) it survives in the 
environment for weeks. Viral infectivity is lost above pH 10.4 or below pH 4.4 
(Zee, 1999). Routine disinfection procedures are effective in destroying CDV 
in kennel, clinic or hospital environments (Greene and Appel 1998).  
 
 
                                
 
Figure 1  Schematic picture of a structure of morbillivirus (ICTVdb, 2006). 
                        
CDV is considered to have one antigenic type (Zee 1999). On the other 
hand, based on phylogenetic analysis of subgenomic F, P, and complete H 
gene sequences, CDV strains can be divided into distinct CDV lineages, 
which are mainly associated with the geographical area from which the strain 
is isolated (Lednicky et al. 2004, Lan et al. 2005, Martella et al. 2006).   
 
2.1.2 Pathogenesis and clinical picture 
 
Both the pathogenesis and the clinical picture of CD depend on the intrinsic 
determinants of both the agent and the host animal (see 2.1.4 below). 
 
Pathogenesis of CD is best studied in the dog (Fig. 2, Appel 1969, Greene 
and Appel 2006). Briefly, invasion of the body is followed within 24 hours by 
multiplication of CDV in local tissue macrophages, spread within these cells 
to the tonsils and bronchial lymph nodes, further replication from 2-4 days 
postinfection (PI), and spread to other lymphoid organs. The virus multiplies 
from 4-6 days PI in the lymphoid follicles of the spleen, in the lamina propria 
of the stomach and small intestine, and in the Kupffer’s cells in the liver, 
which is accompanied by an initial fever 3-6 days PI. Further spread of CDV 
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to epithelial and central nervous system (CNS) tissues 8-9 days PI depends 
on the immune status of the dog, and most likely takes place both as a cell-
associated and plasma-phase viremia. 
 
The clinical picture in all susceptible species manifests most frequently in 
respiratory, gastro-intestinal, integumentary, and CNS systemic signs. 
Biphasic fever and general malaise are often associated with viremia (Deem 
et al. 2000).  
 
The first systemic sign is an initial febrile response at 3-6 days PI, which 
usually goes unnoticed. Mild forms of clinical illness are common, and the 
signs include apathy, loss of appetite, fever, and upper respiratory tract 
infection. Bilateral serous oculonasal discharge may become mucous with 
coughing and dyspnea. In more severe cases the dry cough rapidly becomes 
 
 
 
 
 
Figure 2  Pathogenesis of CD and associated clinical signs (modified from Green and 
Appel 2006)  
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moist and productive. Lower respiratory sounds will be increased. Vomiting 
will follow depression and anorexia, and diarrhea, which may vary in 
consistency from watery to frank blood and mucus, develops. The 
neurological signs, which vary according the CNS areas involved, can 
coincide with the systemic signs, but usually begin 1-3 weeks after recovery 
from systemic illness, and are typically progressive. The neurological signs 
may emerge several months later, and without any preceding systemic signs. 
The presence of neurological signs strongly determines the prognosis for 
CD. 
 
Other signs associated with CD infections of dogs include vesicular or 
pustular dermatitis in puppies, and nasal and digital hyperkeratosis (‘hard 
pads’). CDV infection before the eruption of permanent dentition may cause 
enamel hypoplasia characterized by irregularities in the dental surface of 
permanent teeth.  
 
2.1.3 Laboratory confirmation of the clinical suspicion of CD 
 
Clinical suspicion of distemper can be confirmed by detecting either CDV or 
a specific immune response in samples from the affected animal. Detection 
of CDV from smears of the conjunctiva, tonsillar or genital epithelium using 
immunofluorescent (IF) techniques is possible only within the first 3 weeks 
PI, while systemic clinical signs are apparent. As antibody titres rise in 
association with clinical recovery, the virus will either be masked by 
antibodies or will disappear from the epithelium. The sensitivity of the IF 
technique is no more than 40% (Blixenkrone-Møller et al. 1993, Leisewitz et 
al. 2001). Immunohistochemistry can be used to demonstrate CDV antigens 
in foot pad or skin biopsies, or in samples of spleen, tonsils, lymph nodes, 
stomach, duodenum, bladder and brain taken post-mortem (Greene and 
Appel 2006). The reverse-transcriptase-polymerase chain reaction (RT-PCR) 
can demonstrate CDV from buffy coat cells of acutely-infected dogs and from 
serum, whole blood, cerebrospinal fluid (CSF) or urine of dogs with systemic 
or neurological CD (Shin et al. 1995, Frisk et al. 1999, Saito et al. 2006). RT-
PCR can be applied for the detection of CDV from smears of epithelial cells 
and from other tissue samples. A positive RT-PCR result is indicative of CD 
infection, whereas a negative one can result from various reasons. In the 
case of recently spray-vaccinated fur animals, a positive IF or RT-PCR result 
from epithelial smears of the respiratory tract may also be due to a vaccine 
strain.  
 
Although virus isolation (VI) is the gold standard for the detection of the 
agent, it is not straightforward with CDV. Virulent CDV requires adaptation 
before it grows in routinely-used epithelial or fibroblast cell lines. The best 
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results with virus isolation are achieved by direct cultivation of buffy coat 
cells or other target tissues from the infected host together with mitogen-
stimulated dog lymphocytes (Greene and Appel 2006). Ferret inoculation has 
been used in the past, when other laboratory procedures have not been 
available (Pearson and Gorham 1987).  
 
CDV infection can be confirmed by demonstrating specific antibodies to the 
agent. A four-fold rise in the antibody level of paired sera taken 10 to 21 days 
apart is indicative of the infection. However, this method is not suitable for 
detecting a recent infection, since titres are often already high at the first 
sampling and a four-fold rise cannot therefore be demonstrated. Instead, the 
detection of CDV-specific IgM is indicative of a recent infection. IgM is 
measurable for up to 3 months PI and 3 weeks after the first vaccination. 
ELISA methods for measuring IgM are available (Blixenkrone-Møller et al. 
1991, von Messling et al. 1999, Soma et al. 2003, Latha et al. 2007). 
Increased CDV antibody in CSF is definitive evidence of a neurological CDV 
infection provided that the blood-brain barrier is intact (Greene and Appel 
2006).  
 
2.1.4 Epidemiology 
 
Because CDV does not persist in an infectious form after the resolution of an 
infection, and both infection and vaccination result in long-lasting immunity, a 
constant source of susceptible individuals is required for proliferation of CDV 
in the population. It has been estimated that at least 300 000 individuals are 
needed to maintain measles virus in circulation (Black, 1991). Considering 
the wide host range of CDV, the circulation of the virus does not solely 
depend on the size of the dog population but on the size of the combined 
total population of all susceptible species in the area. Furthermore, the 
contact structures of among those species will be crucial for the continued 
presence of the virus.   
 
Intrinsic determinants of the hosts and the agent  
The infection rate is estimated to be significantly higher than the disease 
rate, and over 50% of infections in domestic dogs may be subclinical 
(Rockborn 1958a, Greene and Appel 2006). The prevalence of CD in urban 
dogs is highest between 3 and 6 months of age. However, in fully susceptible 
populations CDV is capable of causing mortality in dogs of all ages (Gorham 
1966, Böhm et al. 1989). Brachiocephalic breeds of dogs have been reported 
to have a lower prevalence of disease, mortality and sequelae compared 
with dolichocephalic breeds (Greene and Appel 1998). Among farmed mink, 
pastel mink is more susceptible to CD than the ordinary dark form of the 
species (Pearson and Gorham, 1987). Gender does not play a significant
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role in the susceptibility to CD. CD produces a long-lasting immunity in dogs 
that survive the infection. Maternal antibodies received mainly in colostrum 
have a half-life of 8.4 days and will usually be absent by the age of 12 to 14 
weeks (Greene and Appel 1998). In utero or tranplacental infections of CD 
do occur. The outcome of the infection in these cases depends on the stage 
of gestation. 
 
There is no published information of in vivo ID50 of the virus. However, in 
experimental conditions clinical disease has been induced by inoculating  5 x 
103 dog lung macrophage ID50 of virulent CDV strain intranasally in specific-
pathogen-free 4-month-old male beagle dogs (Appel et al. 1982). No 
quantitative data on the virulence of the agent, for example in the form of 
LD50, have been published. The mortality rate in naïve dog populations may 
rise to 80% (Böhm et al. 1989), so that qualitatively the virulence can be 
regarded as at least moderate to high. The case fatality rate in domestic 
ferrets (Mustela putorius furo) approaches 100% (Deem et al. 2000). 
However, virulence differs between CDV strains (Appel et al. 1984a). 
 
Host-agent relationship in the disease 
The length of the latent period (the time from infection to when the individual 
becomes infectious to others) is typically 1 week, while that of the infectious 
period is 2-3 weeks (1 week before and 1-2 weeks after the onset of signs), 
and in rare cases 60-90 days. The incubation period (the time from infection 
to clinical signs) is frequently 1-2 weeks. Urine and saliva of experimentally-
infected dogs have been shown to be infective from day 6 to day 22 PI, and 
from day 7 to day 41 PI, respectively (Shen et al. 1981).   
 
CDV does not establish true carrier states but the virus may be 
demonstrated after the clinical illness for longer periods in epithelial cells and 
macrophages of the lower respiratory tract. It can also persist for at least 60 
days in the skin, footpad and CNS (Greene and Appel 2006).  The 
epidemiological significance of these findings remains inconclusive. 
 
Antigenic drift in the wild-type CDV strains could cause increasing numbers 
of outbreaks in dog and wild animal populations. Several genotypes of CDV 
have been shown to simultaneously circulate in a population (Gemma et al. 
1996, Haas et al. 1999, Lednicky et al. 2004, Martella et al. 2006). However, 
CDV is considered to have only one antigenic type (Zee 1999). Haas et al. 
(1999) found no major diversity in H genes and neutralisation assays 
between recent wild-type isolates and the vaccine strain. On the other hand, 
serum from a dog infected with the Onderstepoort strain reacted at a low 
level against two Japanese field CDV isolates in an immunoperoxidase
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assay (Gemma et al. 1996). The biological significance of these findings 
needs verification. 
 
Transmission of CDV 
CDV is most abundant in the respiratory exudates of infected animals and is 
mainly transmitted by aerosol or droplet exposure. Direct or indirect contacts 
between recently infected (subclinical or clinical) and susceptible animals 
sustain the virus in the population. In temperate climates the highest 
incidence has been reported during the colder months (Rockborn 1958b, 
Gorham 1966, Glardon and Stöckli 1985). This may be attributed to the 
ability of the virus to survive longer in a cool, shady environment, which may 
increase the chances of indirect transmission.  
 
The basic reproduction number R0, defined as the number of secondary 
cases caused by one primary case in a population consisting entirely of 
susceptible individuals (Anderson and May 1982), is a  useful measure of the 
transmission of a pathogen in a population. As a formula, R0 can be thought 
to be composed of the probability of transmission during a contact (β) 
multiplied by the frequency of contacts per time unit (c), multiplied by the 
duration of the infectious period (D) (Woolhouse and Bundy 1997). R0, or 
rather the net or effective R in real-life situations, is frequently considered as 
a threshold parameter: when R < 1 the infection will tend to die out without a 
major outbreak. When R > 1, the chance of a major outbreak exists (De Jong 
and Bouma 2001). However, R is extremely sensitive to heterogeneities 
created by the spatial structure of populations (Dobson and Foufopoulos 
2001), by the age and contact structures in populations, and by a variety of 
ill-defined management and behavioural factors. There are no published 
assessments of R for CD in any settings, but the R0 for phocine distemper is 
2.8 and for measles in the range of 11-18 (Swinton et al. 1998, Woolhouse 
and Bundy 1997).  
 
Occurrence and host range 
CD has a worldwide distribution. CDV is able to infect practically all the 
families of terrestrial carnivores of the order Carnivora. It has also been 
associated with mass-mortalities of Baikal seals (Pusa former Phoca sibirica) 
and Caspian seals (Pusa former Phoca caspica), which belong to the family 
Phocidae of the Carnivora (Osterhaus et al. 1989, Kennedy et al. 2000, 
Figure 3, Table 2). Furthermore, CDV-induced fatal encephalitis has been 
reported in a Japanese macaque (Macaca fuscata) and collared peccaries 
(Tayassu tajacu), which belong to the family Cercopithecidae in the order 
Primates and to the family Tayassuidae in the order Artiodactyla, 
respectively (Deem et al. 2000). Experimental CDV infection in domestic cats 
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(Felis silvestris catus) and pigs (Sus scrofa) resembles the infection of dogs 
with attenuated CDV, but neither natural infection nor clinical disease in the 
cat has been reported (Appel et al. 1974, Harder and Osterhaus 1997). 
Despite the wide host range, dogs are the principal reservoir host for CDV 
(Greene and Appel 2006). 
 
In Finland, CD is known to have occurred in both dogs and fur animals 
(mink) as early as in the 1950s and the 1970s (Estola 1964, Loikala and 
Kangas 1988). In 1985-1987, fur farms suffered from a widespread epidemic 
that originated from imported foxes, but the disease did not spill over to dogs 
and was finally controlled by mass vaccinations of all fur animals in the most 
important fur-farming areas. As a consequence, distemper in fur animals 
became a notifiable disease in Finland (Loikala and Kangas 1988). 
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Figure 3  Phylogenetic tree of the families in the order Carnivora. The families with 
species reported to be susceptible to CDV are in bold italic (adopted from Flynn et al. 
2005, modified according to Appel and Summers 1995, Deem et al. 2000). 
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Table 2  Species that have been reported to be susceptible to CDV in the order 
Carnivora (Appel and Summers 1995, Deem et al. 2000, Loikala and Kangas 1988, 
Mos et al. 2003). 
Family  Genus  Species     
Felidae   Panthera   African lion (Panthera leo)     
    Tiger (Panthera tigris)   
    Leopard (Panthera pardus)   
    Jaguar (Panthera onca)   
  Puma  Cougar, mountain lion, puma (Puma concolor) 
Viverridae  Arctictis  Binturong (Arctictis binturong)   
  Paguma  Masked palm civet (Paguma larvata)  
Hyaenidae Crocuta  Spotted hyena (Crocuta crocuta)  
Canidae  Alopex  Arctic/blue fox (Alopex lagopus)   
  Vulpes  Red fox (Vulpes vulpes)   
    Kit fox (Vulpes macrotis macrotis)  
    Fennec fox (Vulpes zerda)   
  Nyctereutes Raccoon dog (Nyctereutes procyonoides)  
  Otocyon  Bat-eared fox (Otocyon megalotis)  
  Urocyon  Grey fox (Urocyon cinereoargentus)  
  Chrysocyon Maned wolf (Chrysocyon brachyurus)  
  Speothos  South American bush dog (Speothos venaticus) 
  Canis  Wolf (Canis lupus)    
    Domestic dog (Canis lupus familiaris)  
    Australian dingo (Canis lupus dingo)  
    Coyote (Canis latrans)   
  Lycaon  African wild dog (Lycaon pictus) 
Ursidae  Ailuropoda Giant panda (Ailuropoda melanoleuca)  
  Ursus  Black bear (Ursus americanus floridanus)  
    Grizzly bear (Ursus arctos horribilis)  
    Marsican bear (Ursus arctos marsicanus)  
    Polar bear (Ursus maritimus)   
  Tremarctos Spectacled bear (Tremarctos omatus)  
Phocidae  Pusa  Baikal seal (Pusa sibirica)   
    Caspian seal (Pusa caspica)   
Ailuridae  Ailurus  Red panda (Ailurus fulgens)   
Mephitidae Mephitis  Striped skunk (Mephitis mephitis)  
Procyonidae Procyon  Raccoon (Procyon lotor)   
  Potos  Kinkajou (Potos flavus)   
Mustelidae Lutra  European otter (Lutra lutra)   
    River otter (Lutra canadiensis)   
  Meles  European badger (Meles meles) 
  Taxidea  American badger (Taxidea taxus)  
  Mustela  American mink (Mustela vison)   
    European mink (Mustela lutreola)  
    Ferret (Mustela putorius)   
        Black-footed ferret (Mustela nigripes)   
 
Control of CD 
Vaccination remains the principal means of controlling the disease. The 
widespread use of modified live vaccines (MLV) has greatly reduced the 
incidence in dogs (Chappuis, 1995). Vaccination is also used to control CD
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among several species of farmed fur animals, ferrets kept as pets and 
among a wide range of other susceptible animal species kept in zoos (Appel 
and Summers 1995, Gorham and Wilson 1997). On the other hand, post-
vaccinal encephalitis in dogs (Cornwell et al. 1988) and vaccination-induced 
cases of CD have been reported in several species (Bush et al. 1976, 
Carpenter et al. 1976, Appel and Summers 1995, Halbrooks et al. 1981, 
Saari et al. 1999, Ek-Kommonen et al. 2003a). Maintaining a high vaccine 
coverage in populations of dogs and other susceptible species, as well as 
the use of the most potent vaccines available, is vital for the control of CD 
(Chappuis 1995, Harder and Osterhaus 1997). Dogs infected with CDV 
should be isolated from healthy ones (Greene and Appel 2006). Furthermore, 
as no vaccination strategy can eliminate the gap in protection between the 
passive maternal immunity and an active immunity, prophylactic measures 
should include the isolation of young dogs from the general dog population 
until vaccine-induced protection has been reached (Blixenkrone-Møller et al. 
1993).   
 
For CD control, fur animal farms form a very specific setting: tens to 
thousands of various CD susceptible species are kept at a high density. 
Furthermore, the population structure varies greatly according to the season: 
the size of a population more than triples in March-May, and after pelting in 
December only breeding animals are left. In addition to vaccination, strict 
biosecurity measures such as isolation and quarantine are necessary at fur 
farms (Pearson and Gorham 1987). The risk period for CD (immunity gap) 
varies from a few weeks in mink farms to some months in fox farms, because 
the breeding period is longer in fox farms compared to that in mink farms 
(Loikala and Kangas 1988). 
 
In Finland, dogs are recommended to be vaccinated as follows: the first two 
vaccinations are given with a 4-week interval starting at the age of 12 weeks, 
and the third vaccination is given at the age of 12 months. Thereafter, 
booster vaccinations are given 1- to 3-year intervals. If the infectious 
pressure is high, puppies can be vaccinated starting at the age of 6-8 weeks, 
followed by vaccination at 3- to 4-week intervals until the puppy is 12-16 
weeks of age. Mink, fox and raccoon dogs from unvaccinated dams can be 
vaccinated at 8-9 weeks of age, and those from vaccinated dams at 10-14 
weeks of age. Dams should be vaccinated at latest 3 weeks before the 
beginning of the breeding season. Annual boosters are recommended. 
 
The impact of vaccination can also be examined in terms of the reproduction 
number R. Vaccination evidently reduces the number of susceptible 
individuals in the population and thus decreases the probability of 
transmission (β) and furthermore shortens the duration of the infectious 
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period (D). By vaccinating a large enough portion of the population it is 
possible to reduce R below 1 (De Jong and Bouma 2001). 
 
2.2 Distemper vaccines 
 
Active immunization against CD has been practised since Puntoni in 1923 
described the use of formalin-inactivated CDV-infected dog brain tissue 
(reviewed by Appel 1999). However, active immunization was not successful 
before MLVs became available in the 1950s.  All commercial CD vaccines 
available for dogs are multivalent vaccines that, besides the CDV 
component, also contain some of the following components: inactivated 
canine adenovirus type 1 (CAV-1) or attenuated CAV-2, attenuated or 
inactivated canine parvovirus, attenuated canine parainfluenza viruses and 
Leptospira canicola-icterohaemorrhagiae bacterin. Nowadays, most of the 
virus antigens included in the vaccines tend to be of the modified live type. 
CD vaccines are administered either subcutaneously or intramuscularly. 
Canine distemper vaccines registered to be used in mink usually contain only 
CDV antigen and are administered subcutaneously, intramuscularly or by 
aerosol-spray. Since no registered CD vaccines exist for other farmed fur 
animal species, mink CD vaccines are used. 
 
2.2.1 Attenuated live viral vaccines  
 
In MLV the micro-organism is rendered avirulent by attenuation, but it is still 
able to replicate in the host. Conventional attenuation is achieved by serial 
passage of the virus in a cell culture. Vaccination with an MLV closely mimics 
natural infection; it stimulates both humoral and cellular immune responses, 
and induces immunological memory (van Oirschot 1997). The majority of CD 
vaccines currently contain either the egg-adapted, avian cell culture-adapted 
or Vero cell-adapted Onderstepoort strain (Haig 1956), or the Rockborn 
strain, which is produced in canine cell cultures (Rockborn 1959). As there 
are problems with the safety of some MLVs in dogs and especially in other 
species, a new generation of CD vaccines has been and is being developed.   
 
2.2.2 Recombinant and DNA vaccines  
 
Since antibodies raised against H and F glycoproteins of CDV play an 
important role in the protection against CD (Norrby et al. 1986), it is clear 
that these antigens should be included in the new generation of CD 
vaccines. Improved adjuvants or other immune-stimulating complexes are 
needed in formulation of these recombinant protein vaccines in order to 
reach sufficient efficacy (de Vries et al. 1988, Visser et al. 1992, Fischer et 
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al. 2003). Vaccines produced by recombinant techniques have been shown 
to be efficient and safe (Taylor et al. 1991, Pardo et al. 1997, Welter et al. 
2000). The canarypox vector, which is non-replicating in mammals, has been 
used to express genes of CDV H and F glycoproteins in a recombinant CD 
vaccine currently available for dogs in the USA (Pardo et al. 1997). This 
vaccine has been successfully tested in ferrets (Stephensen et al. 1997). The 
VN antibody levels induced by recombinant vaccines are not as high as with 
well-performing MLVs (Pardo et al. 1997), and the duration of immunity is 
probably shorter than that of MLV (Schultz 2006). DNA vaccines are in the 
experimental stage (Sixt et al. 1998, Cherpillod et al. 2000, Fischer et al. 
2003, Dahl et al. 2004).  
 
2.3 Response to vaccination on individual and population levels 
 
The outcome of an infection depends on the properties of the virus and the 
host’s immune responses. Naïve individuals can recover from the infection 
caused by virulent CDV provided that their humoral and especially cellular 
immune reactions are vigorous enough (Appel et al. 1982). The MLVs induce 
immune responses that are in principle very similar to those occurring after 
natural infection. The outcome of the vaccination depends on the properties 
of the vaccine strain, on the formulation of the vaccine, and on several other 
factors. Both cellular and humoral immunity are important in the protection 
against CDV (Appel 1969, Krakowka et al. 1975, Appel et al. 1984b). 
 
2.3.1 Individual level 
 
Humoral immunity can be demonstrated by measuring the titre of virus 
neutralising (VN) antibodies against CDV in the serum. These antibodies are 
raised against the viral glycoproteins H and F. The presence and titre of the 
neutralising antibodies correlate with the level of protection against CD 
(Norrby et al. 1986). Vaccination with MLVs also elicits antibodies against 
other viral antigens, but the role of these in protective immunity is 
inconclusive. The neutralising antibodies can be detected 6-10 days post 
vaccination in the serum, and their titres peak between 14-21 days post 
vaccination (Appel 1987), and persist for several years (Olson et al. 1997b, 
Coyne et al. 2001). Puppies with maternal antibody titres higher than 1:100 
were protected against CDV infection (Gillespie 1996). Susceptible dogs that 
developed titres of at least 1:100 by day 14 after challenge with virulent CDV 
survived (Appel 1969). In another study, susceptible dogs that on average 
developed a titre of 1:8 between 10-21 days PI survived (Appel et al. 1982). 
According to Greene and Appel (2006), a VN antibody titre of 1:20 is 
considered protective after vaccination. Among the variety of serological 
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methods applicable for the detection of the humoral response or 
measurement of antibody titres, immunofluorescence assay and ELISA–
based methods are nowadays perhaps the most common. The efficacy of a 
vaccine can be indirectly assessed by determining the average level of VN 
antibodies in the vaccinated population. 
 
Several methods have been used to measure cellular immunity against 
CDV (Appel et al. 1984b, Krakowka and Wallace 1979, Shek et al. 1980). 
Virus-specific cell-mediated immunity can be demonstrated from 6-18 days 
post vaccination. It reaches maximal levels between 7-10 days post 
vaccination (Krakowka and Wallace 1979, Shek et al. 1980). However, the 
use of these methods is hampered by the overall short duration of the 
responses (Appel et al. 1982); furthermore, the methods require 
considerable expertise and are not easily amenable to high-throughput 
procedures.  
 
2.3.2 Population level 
 
On the population level, the response to vaccination can be described as the 
proportion of the vaccinated population that has developed sufficient 
immunity against infection, i.e. the vaccine take (Woolhouse and Bundy 
1997). In addition to the average levels of VN antibodies elicited by a 
vaccine, its field efficacy is reflected in the take. Herd immunity (HI), defined 
as the proportion of subjects with immunity in a given population (John and 
Samuel 2000), is a result of the immunity induced both by vaccination and 
natural infection in the population. The part of HI induced by vaccination 
heavily depends on both the overall vaccine coverage and on the takes of 
the employed vaccines. Other factors that contribute to vaccine-based HI are 
the duration of the induced immunity and the average life expectancy of the 
vaccinees. The higher the HI, the less probable it will be that a susceptible 
individual encounters and perpetuates the infection (De Jong and Bouma 
2001). 
 
2.4 Reported assessments of vaccines, vaccine coverage and 
outbreaks 
 
2.4.1 CD vaccines  
 
There have been only a few reports of the average levels antibodies reached 
with vaccination. Floss and Schrag (1995) reported significantly higher titres 
in 13 puppies vaccinated with a Rockborn-strain vaccine compared with the 
Onderstepoort-strain vaccinated ones. Gore et al. (2005) reported a 
geometric mean VN titre of 1:193 thirty six months after vaccination among 
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23 beagles vaccinated at 7 and 11 weeks of age. Olson et al. (1988) 
reported geometric mean titres of 1:51 in vaccinated dogs less than 12 
months of age, 1:27 in vaccinated dogs more than 12 months of age, and 1:5 
in unvaccinated dog less than 12 months of age.  
 
On the population level, Kölb et al. (1995) reported IFA titres > 1:20 against 
CDV in 63% of Dohyvac® , 91.7% of Canimed® and 100% of Canlan®, 
Enduracell® and Vetamun® vaccinated groups of puppies (n = 12-13 per 
group). Olson et al. (1988) reported that 78.3% and 80.7% of dogs (n = 259) 
less than 12 months of age vaccinated once and twice, respectively, and 60-
88.2% of vaccinated dogs (n = 244) more than 12 months of age had a titre 
of > 1:16. Among randomly-selected vaccinated dogs (n = 176) representing 
six breeds, 86.1% had a titre of > 1:16 (Olson et al. 1996a). In a large 
population study of vaccinated dogs (n = 1848), the proportion of dogs with a 
titre higher than 1:16 were 66.4% and between 86.7–92% in those 
vaccinated with Dohyvac® and Nobivac® or Candur®, or with several 
vaccines, respectively (Olson et al. 1997a).  McCaw et al. (1998) reported 
that 79% of dogs (n = 117) coming to revaccination had titres of at least 1:96. 
According to Böhm et al. (2004), 89.6% of dogs (n = 144) that had been 
vaccinated more than three years previously had a VN titre higher than 1:16 
against CDV. In a population based study of 207 dogs vaccinated 1 or more 
years previously, Ottiger et al. (2006) observed that 83% had a titre higher 
than 1:16.   
 
2.4.2 Vaccine coverage and outbreaks  
 
In a questionnaire-based study (n = 538) a vaccine coverage of 95.8% was 
observed in Sweden (Olson et al. 1996a). A slightly lower level of 85.4% of 
mixed breed dogs were vaccinated against CD compared to the 97.6% of 
pure-bred dogs. Glardon and Stöckli (1985) reported 179 out of 280 cases 
(63.9%) among vaccinated dogs. Of these, 83% were regarded as properly 
vaccinated. The vaccine coverage before the Danish CD outbreak was 
estimated to be 50%, and 65% of confirmed CD cases were among dogs 
less than 2 years of age. Among these 50 cases, 17 were unvaccinated, 18 
vaccinated and 15 had obscure vaccination records (Blixenkrone-Møller et 
al. 1993). Jozwik and Frymus (2002) reported that 72% and 22% of all CD 
cases occurred among dogs less than 12 months of age and among 
vaccinated dogs, respectively. 
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2.5 Vaccine failures 
 
Despite vaccination, outbreaks of CD continue to occur among vaccinated 
individuals and populations (Glardon and Stöckli 1985, Harder et al. 1991, 
Blixenkrone-Møller et al. 1993, Mori et al. 1994). General reasons for vaccine 
failures are schematically presented in Figure 4. The viability of the modified 
live CDV vaccine strain is essential to successful vaccination. Lyophilized 
tissue culture vaccine strains are stable for 16 months under refrigeration (0–
4 oC), 7 weeks at 20 oC and 7 days when exposed to sunlight at 47 oC. After 
reconstitution, a vaccine virus remains stable for 3 days at 4 oC and 24 hours 
at 20 oC, However, a reconstituted vaccine should be used within one hour 
(Greene and Appel 2006). 
 
 
Vaccination
Correct  
administration 
Incorrect  
administration 
Inappropriate route 
Inactivation of live vaccine 
Animal  
responds 
Prior passive immunisation 
Animal immunosuppressed 
Inadequate vaccine 
Biological variation 
Animal fails 
to respond 
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Wrong vaccine strain 
Nonprotective antigens used 
VACCINE 
FAILURE 
 
Figure 4  General reasons for vaccine failures (Povey 1986, Roth 1999, Tizard 2000)  
 
Results from field studies of CDV vaccinations suggest that even minimal 
levels of maternal antibodies that persist at the time of vaccination may 
impair the ability of dogs to respond to both primary and subsequent 
vaccinations (Blixenkrone-Møller, unpublished data, 1993). On the other 
hand, some CDV vaccines have been shown to break through maternal 
immunity in experimental conditions when basic vaccination was started at 
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the age of six weeks and completed at the age of 10 weeks (Bergman et al. 
2006). Nevertheless, interference by the maternal antibodies is considered to 
be one of the most important reasons for vaccine failures in dogs. 
 
Due to intensive inbreeding, inherited immunodeficiency syndromes are 
probably more common in dogs than has been recognized. They are likely to 
account for an unknown, but important number of vaccination failures (Povey 
1986).   
 
Concurrent infections at the time of vaccination may stimulate the production 
of interferon, block the replication of vaccine virus, or be 
immunosuppressive. Environmental conditions that can be regarded as 
stressful, such as overcrowded conditions or transportation, may inhibit the 
immune response to vaccination. A high environmental temperature and 
humidity that raised the body temperature above the normal average had an 
adverse effect on the immune response of puppies after vaccination 
(Webster 1975). 
 
Antigens applied simultaneously can interact with each other and with the 
vaccinated host. These interactions may enhance or reduce the 
immunogenicity of a particular antigen (Strube 1997). Phillips et al. (1988) 
demonstrated that ML CDV and CAV-1 or -2 in a multivalent vaccine 
suppressed lymphocyte responsiveness. ML parvovirus antigens in 
multivalent vaccines have also been suspected but not proven to be 
immunosuppressive (Greene 1998). 
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3. AIMS OF THE STUDY 
 
 
The aim of the present thesis was to investigate the immunogenicity of 
canine distemper (CD) vaccines both in experimental and in field conditions, 
as well as the occurrence and epidemiological features of CD. More 
specifically, the aim was to 
 
- study the immunogenicity of CD vaccines in dogs and farmed fur 
animals in experimental settings (I, II); 
 
- explore the immunogenicity of CD vaccines in dogs in a sample 
obtained from the field, with special reference to the age, number of 
vaccinations, time since the last vaccination and the vaccine used (III); 
 
- describe the background and causes that led to a severe CD outbreak 
in a vaccinated population (IV, V); 
 
- estimate the level of herd immunity induced by vaccination against CD 
in the contemporary young dog population from 1988-1996 (V); 
 
- pinpoint the critical level of herd immunity for the control of CD (V). 
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4. MATERIALS AND METHODS 
 
 
4.1 Materials 
 
4.1.1 Seroconversion studies (I, II) 
 
Animals and vaccinations 
Study I. Three groups of 25 purpose-bred beagle dogs (altogether 15 litters) 
were each vaccinated with one of the three commercially-available triple 
vaccines at the age of 3 and 4 months at the National Laboratory Animal 
Centre, University of Kuopio. 
 
Study II. Healthy American mink (Mustela vison), raccoon dog (Nyctereutes 
procyonoides), silver fox (Vulpes vulpes) and blue fox (Alopex lagopus) 
young born within a time span of 2-3 weeks were chosen from the population 
of University of Kuopio Research Fur Farm. The young of each species were 
weaned at the age of 5-7 weeks, and placed in cages of the same 
shedhouse at the age of 10-12 weeks. Every other mink female and male of 
the same litter were placed together on opposite sides of the shedhouse. 
With the other species, every other litter according to age was placed on 
opposite sides of the shedhouse. If there were more males than females, the 
extra males were kept alone. Animals on one side of the shedhouse were 
vaccinated with one vaccine and those on the opposite side with another. 
Each fur animal was vaccinated once subcutaneously in the neck, using the 
dose recommended for mink by the manufacturer (1 ml). Two trials using two 
CD vaccines in four (first trial) and two fur animal species (second trial) were 
run. Ages varied within trials between species because all animals and all 
species were vaccinated simultaneously, and breeding seasons differ slightly 
(II). In the first trial, mink (n = 20 + 20) were vaccinated at 12-14 weeks, 
raccoon dogs (19 + 20) at 15-17 weeks, blue fox (20 + 22) at 12-15 weeks 
and silver fox (20 + 20) at 14-16 weeks of age. In the second trial, mink (20 + 
20) were vaccinated at 12-13 weeks of age and silver fox (20 + 20) at 12-15 
weeks of age. 
 
Blood samples 
Study I. Blood samples were drawn from all 75 dogs at the age of 3, 4 and 5 
months and from 8, 6 and 3 dogs in vaccine groups 1, 2 and 3, respectively, 
at the age of 1 year. 
 
Study II. Blood samples were collected from the cephalic vein of Canidae 
species with a vacuum-sampling device; for mink, a claw was cut and 
capillary blood collected openly. Adequate blood samples could not be drawn 
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from all of the animals at every sampling. Animals were monitored daily for 
changes in appetite, growth or any other signs of unthriftiness or clinical 
disturbances by the animal attendants. The staff had no knowledge of which 
animals received the vaccines used in these trials. In the first trial, blood 
samples were collected three times: before vaccination and 1.5 and 2.5-4 
months after vaccination. Some animals were sampled two further times: 8-
10 and 11-12 months after vaccination. In the second trial, blood samples 
were collected five times: before vaccination and 4 times at monthly intervals 
starting one month after vaccination. Some animals were sampled two 
further times: 5 and 6 months after vaccination.   
 
4.1.2 Prevalence studies (III, IV, V) 
 
Laboratory-confirmed CD cases (IV, V) 
Information on the occurrence of CD in dogs in Finland is based on clinical 
samples sent to the National Veterinary and Food Research Institute (EELA).  
 
Vaccinated dogs sampled for the determination of VN titres (III, IV) 
Serum samples were collected from CD-vaccinated dogs between November 
1994 and December 1995 by 230 small animal clinics or clinicians in urban 
and suburban areas of Finland. The name of the owner and the dog, its date 
of birth, gender and breed, the dates of vaccinations, the vaccines used and 
the date of sampling were recorded. The clinicians were also asked to 
comment on the health of the dogs. A total of 5 734 samples were received, 
but as a result of incomplete information and multiple sampling of some of 
the dogs, the number of dogs used in the analysis was reduced to 4 627. 
The dogs sampled several times were included only when they were first 
sampled. The most recent vaccination was ignored if it had been given less 
than three weeks before sampling.    
 
Vaccines and their market shares  
Studies I, III - V. The CD vaccines registered for dogs and available from 
1988-1996 are shown in Table 3. Three CD vaccine brands were in use from 
1987 until 1994: Candur®  (Behringwerke), Canlan® (Langford Laboratories) 
and Dohyvac® (Solvay Animal Health). In February 1995, Dohyvac® was 
withdrawn from the market. Nobivac® (Intervet) and Duramune® (Fort Dodge 
Laboratories) were introduced to the market in February and July 1995, 
respectively. The annual statistics on CD vaccines sold in 1984-1996 and 
monthly statistics on CD vaccines sold in 1994-1996 were obtained from the 
Statistics of the National Veterinary Institute, later the National Veterinary 
and Food Research Institute (EELA). The market shares of the high-take CD 
vaccine brands are presented in Table 9. 
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Table 3 Canine distemper vaccines registered for dogs in 1988-1996 in Finland. CDV 
strains abbreviated as Rockborn (RO) and Onderstepoort (OP). Minimum titre of CDV 
per dose expressed as TCID50 (tissue culture infectious dose) except EID50 (egg 
infectious dose) for Dohyvac®. 
 
 
Vaccine CDV strain             Cell line 
Minimum   
titre of 
CDV per 
dose 
Other 
antigens in 
the vaccine 
Adjuvant Manufacturer 
                           
Candur® SH RO                    
Canine kidney 10
3 
inact.1       
freeze-dried  
CAV-12 
Al(OH)3 Behringwerke 
Candur® SHP   
as above + 
inact.CPV3 
Al(OH)3 
and 
Al2(PO4)3   
 
                 
Canlan®-3 OP type                 
Vero  10
3.7  inact.CAV-1 and CPV 
Al(OH)3    
and L-80 
Langford 
Laboratories 
Canlan®-4   
as above +    
ML4 CPI5   
Dohyvac® DA2 
OP type       
Chicken 
embryofibroblasts 
102.5  ML CAV-2 No adjuvant 
Solvay 
Animal 
Health 
Dohyvac® DA2+P  as above + inact.CPV  Al(OH)3   
Dohyvac® DA2Pi  ML CAV-2     and CPI 
No 
adjuvant  
Dohyvac® DA2Pi+P  as above + inact.CPV Al(OH)3   
Duramune®-4 RO type          Canine kidney       10
3.3  
ML CAV-2,    
CPV and 
CPI 
No 
adjuvant       
Fort Dodge 
Laboratories 
Nobivac® DHP OP type             Vero 10
3.3  ML CAV-2     and CPV 
No 
adjuvant       Intervet 
1 inactivated                                                                                                                             
2 canine adenovirus 1 or 2     
3 canine parvovirus       
4 modified live     
5 canine parainfluenza virus     
      
 
Study II. The three commercial mink distemper vaccines containing freeze-
dried modified live egg-adapted canine distemper virus are shown in Table 4.
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Table 4 Commercial mink distemper vaccines containing a freeze-dried modified live 
egg-adapted CDV strain used in seroconversion study II. Vaccine 3 was intended for 
use in both mink and ferret. Minimum titre of CDV per dose is expressed as EID50 (egg 
infectious dose). 
 
 
 
Vaccine Minimum titre of CDV per dose Manufacturer 
 
 
Distemink® 103.0  United Vaccines 
 
 
Distem®-R-TC 103.5  Schering Corporation  
 
Vaccine 3 103.7  Gift from a manufacturer  
 
Dog demographics 1985-2006 (V) 
The annual statistics on the numbers of dogs registered in 1975 to 2006 
were provided by the Finnish Kennel Club. The proportion of non-registered 
dogs in the population was estimated to e a constant 20% and each dog was 
assumed to have a life-expectancy of 10 years. These estimates were 
obtained from an expert in the Finnish Kennel Club. The age structure of the 
population was determined using the annual numbers of registered dogs, 
starting from 1975. In this way the total size and age structure of the 
registered population could be calculated from 1985 onwards. The 
calculations were performed using the spreadsheet program MS Excel 2000 
(Microsoft Corporation, USA).   
 
4.2 Methods 
 
Laboratory confirmation of CD (IV, V) 
Clinical suspicion of CD was confirmed by demonstrating the presence of 
CDV in the epithelial cells from the mucous membranes of conjunctiva, 
genital tract, trachea or urinary bladder. The epithelial cells were transferred 
onto microscope slides, air-dried and fixed in acetone. An indirect 
immunofluorescence assay (IFA) was performed, using a mixture of 
monoclonal antibody clones 4.100 and 3.851 (Claes Örvell, Huddinge 
University Hospital, Sweden) directed against the nucleoprotein of the CD 
virus and rabbit anti-mouse IgG fraction conjugated with fluorescein 
isothiocyanate (Dako, Denmark). 
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Determination of virus-neutralising antibodies (I, II, III, IV) 
The level of virus-neutralising antibodies against CDV was determined with a 
modified version of the microneutralisation test described by Appel and 
Robson (1973). Briefly, the heat inactivated sera were diluted fourfold (1:8, 
1:32, 1:128 and 1:512) and mixed with an equal volume of medium 
containing 100 TCID50/ml of the Onderstepoort strain of CDV and incubated 
at 37 oC for one hour. The mixture was then inoculated into Vero cells and 
incubated again at 37 oC for one hour; after this incubation, maintenance 
medium was added to the wells. A standard virus titration and a positive 
control serum were included in each test series. The test was read 
microscopically after six days. The highest serum dilution without a 
cytopathogenic effect was recorded as its reciprocal (titre < 1:8 = 1, 1:8 = 8, 
1:32 = 32, 1:128 = 128 and > 1:512 = 512). The value 1 was used for titres < 
1:8 to simplify the statistical analysis. Titres below 8 were classified as 
undetectable for virus-neutralising antibodies, and those of 8 or above as 
detectable.  
 
Vaccine usage and immunogenicity groups, and redistribution of the 
vaccines into low- and high take groups (III) 
The dogs were grouped according to the canine distemper vaccine used into 
vaccine usage groups. Dogs vaccinated with a single vaccine brand were 
grouped together and designated according to the brand. The geometric 
mean titre of neutralising antibodies for all single vaccines was 29. This 
reciprocal value was used as a cut-off point to divide the vaccines according 
to their geometric mean titres. Canlan® and Dohyvac® induced low titres and 
are here referred to as low-take, whereas Candur® , Duramune® and 
Nobivac® induced high titres and are referred to as high-take vaccines. Dogs 
vaccinated with more than one brand of vaccine were designated as mixed 
low-take or mixed high-take; the former consisted of dogs vaccinated with 
Canlan® and Dohyvac® and the latter consisted of dogs vaccinated with any 
other combinations. These single low and high, and mixed low and high 
groups are referred to as immunogenicity groups.  
  
Vaccine coverage (IV, V) 
Estimation of the number of vaccines needed annually was based on 
contemporary vaccination recommendations. In the 1980s, puppies were 
vaccinated for the first time at the age of 3-4 months and the second 
vaccination was given one year later. In the 1990s, two vaccinations with a 
4-week interval were given, starting at the age of 3 months, and a third 
vaccination was administered at the age of one year. After these basic 
vaccinations each dog was assumed to receive 3 booster vaccinations 
approximately triennially. This yielded the number of vaccines needed, which 
was then compared with the number of vaccines sold to obtain an estimate 
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of the annual vaccine coverage from 1988-1993 and the monthly coverage 
from 1994-1996. Uniform vaccine coverage was assumed in the population.  
 
Herd immunity (V) 
The take of each vaccine was calculated as the proportion of dogs with 
detectable levels of neutralising antibodies against CDV, as examined in III. 
The vaccine takes were calculated separately for the age groups < 1 year 
and 1-2 years, and are shown in Table 5.  
 
 
Table 5  Take (proportion of vaccinated dogs with a detectable level of neutralising 
antibodies against CDV, titre > 1:8) of the CD vaccine brands among dogs < 1 year of 
age and dogs 1-2 years of age in 1994-1995 (study III), which was used in calculating 
herd immunity (study V). 
 
Age Candur® Canlan® Dohyvac® Nobivac® Duramune®   
< 1 year 0.97 0.56 0.46 0.89 0.87   
1-2 years 1 0.8 0.62 NT* NT   
* not tested, take of Nobivac® and Duramune® in dogs < 1 years was used for dogs 1-2 years of age as well 
 
 
To obtain a uniform time scale for the calculations, the annual numbers of 
registered dogs were divided by 12 to determine the annual average monthly 
values and the monthly estimates were interpolated linearly between these 
annual average values. The numbers of immune dogs in age groups < 1 year 
and 1-2 years were calculated separately for each monthly time point with: 
                            5 
Nrimmunes = 1.25  * n  * vc  *  Σ ( mj * vtj)  
                            j = 1 
where  
the constant 1.25 is used to obtain the total size of the age group 
using the known number of registered dogs (20% of the 
population estimated to be non-registered) 
n = number of registered dogs in the age group 
vc = calculated vaccine coverage (upper limit 1) 
mj= market share of the jth vaccine 
vtj = take of the jth vaccine in the age group 
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The HI was then calculated on the monthly level among dogs less than 2 
years of age with: 
 
     HI (%) = 100 * (Nr1 + Nr2) / N 
where 
Nr1 = number of immune dogs < 1 year of age 
Nr2 = number of immune dogs 1-2 years of age 
N = total number of dogs less than 2 years of age 
 
Calculation of the number of immunes and HI was performed with the 
spreadsheet program MS Excel 2000 (Microsoft Corporation, USA). 
 
Grouping variables and the variables compared between groups (III) 
The groups used for the statistical comparisons and the variables compared 
among the groups are summarized in Table 6.   
 
Table 6  The grouping variables and the variables compared between groups in 
statistical analysis in the seroprevalence study (III). The three age groups of dogs 
were: 1 = less than 1 year, 2 = one to two years, and 3 = over two years. The three 
groups for the time since the latest vaccination were: 1 = less than year, 2 = one to two 
years, and 3 = over two years.  Immunogenicity groups were single high = dogs 
vaccinated with a single high-take vaccine, single low = dogs vaccinated with a single 
low-take vaccine, mixed high = dogs vaccinated with at least two vaccine brands and at 
least once with a high-take vaccine, and mixed low = dogs vaccinated only with low-
take vaccines.  
 
 
Grouping variable     Variable compared      between groups   
 vaccine usage     titre*   
 age (1-3)   titre*  
 gender   titre  
 time since the latest vaccination (1-3) titre  
 number of vaccinations (1-4)   titre*  
 vaccine usage   
mean no of 
vaccinations*  
 vaccine usage   age in days*  
 
immunogenicity groups 
stratified by number of 
vaccinations   
titre* 
 
 
immunogenicity groups 
stratified by age   titre*  
 * significant association          
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Statistical analysis 
Study I. The Yates-corrected Chi-square test was used to compare the 
number of dogs with titre > 1:8 and < 1:8 after vaccination with different 
vaccines. 
Study II. The mean and standard deviation (S.D.) of the titres were 
calculated from log10-transformed reciprocal values. Statistical tests were 
applied to the transformed values. The antibody levels among the groups of 
vaccinees stratified according to sampling time, species and trial were 
compared with the Student’s two-sample t-test (two-tailed). Statistical 
significance was inferred with p < 0.05.  
Study III. The geometric mean titres and the proportion of dogs with a 
detectable VN antibody titre were calculated and compared among the 
groups displayed in Table 6. Kruskal- Wallis one-way nonparametric analysis 
of variance was used with the titre data and one-way analysis of variance 
with Tukey’s comparison of means was used to compare the number of 
vaccinations and age among the vaccine usage groups (Sokal and Rohlf 
1995). The representativeness of the sample was tested by comparing the 
vaccine usage and breed distribution of the sample with those of the whole 
country, by using the Kolmogorov-Smirnov equality of distribution test (Sokal 
and Rohlf 1995).   
Study IV. The observed numbers of diseased dogs vaccinated against CD 
with available vaccines were compared with those which would have been 
expected from the market shares of the vaccines, on the assumption of 
uniform efficacy, by the Chi-square test.  
Studies I – IV. The software packages used were Statistix for Windows 
(Analytical Software, USA) and Unistat Statistical Package, Version 4 
(Unistat, UK). 
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5. RESULTS 
 
 
5.1 Seroconversion studies (I, II) 
 
Results of the seroconversion studies in beagle dogs (I) and four fur animal 
species (II) are combined in Figures 5 and 6. From study II the sampling 
times with the highest number of samples were chosen. Altogether, 10 out of 
161 and 3 out of 80 samples were missing from the sampling at 2.5-4 and 3 
months, respectively.  
 
Candur®  induced significantly higher VN titres than Dohyvac® or Canlan® (p 
< 0.001). All the dogs in Candur®  group had a VN antibody titre > 1:32 1 
month after the first vaccination, whereas nine out of twenty-five and four out 
of twenty-five dogs in Dohyvac®- and Canlan®-vaccinated groups failed to 
produce VN antibodies even one month after the second vaccination. The 
proportions of dogs with VN antibodies differed significantly between 
Dohyvac® and Canlan® vaccinated groups; both vaccines contained the 
Onderstepoort strain.  
 
Figure 5 The log10 reciprocal geometric mean titres achieved with the vaccines in the 
seroconversion studies (I and II). Bars represent the respective standard deviations. 
Beagle dogs were sampled one month after the second vaccination, blue fox and 
raccoon dog 2.5–4 months after vaccination, and vaccine 3 vaccinated mink and silver 
fox 3 months after vaccination. The results for Distemink®-vaccinated mink and silver 
fox are combined from two trials in which animals were sampled 2.5–4 and 3 months 
after vaccination.    
 
Distemink® induced high geometric mean titres in all four species, and the 
proportion of animals with a detectable level of VN antibodies was > 95%. 
Although the proportion of Distem®-R-TC vaccinated animals with a 
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detectable level of VN antibodies was high (> 90%) in all species, the 
geometric mean antibody titres in the silver fox and blue fox were less 
promising. Distemink® induced a significantly higher level of VN antibodies 
than Distem®-R-TC in all four species: mink, silver fox, blue fox and raccoon 
dog. Although performing satisfactorily in vaccinated minks, vaccine 3 
induced antibodies at best in only 60% of silver foxes four months after 
vaccination. Samples were obtained from all silver foxes vaccinated with 
Distem®-R-TC or vaccine 3 at every sampling. However, difficulties in 
sampling the other fur animals meant that samples were not obtained from 
all the individuals at each sampling.  
 
 
Figure 6  Proportions of vaccinated animals with detectable antibody titres in the 
seroconversion studies (I and II).  Sampling times are the same as in Fig. 5. 
 
 
5.2 Seroprevalence study (III) 
 
5.2.1 Representativeness of the field sample  
 
According the registration statistics of the Finnish Kennel Club, dogs from 
262 breeds were registered from 1990-1994. Ten or more individuals were 
registered for 231 breeds during these five years. Samples were obtained 
from 208 breeds of dogs. No significant differences were found between 
proportions of the vaccines used in the sample and in the country as a 
whole. The 30 breeds used for the comparison constituted 63% of the 
sample and 61% of the registrations in the whole country from 1990 to 1994. 
No significant differences between the breed distribution of the sample and 
that of the whole country were found, even though the breeds used for 
hunting, such as the Finnish hound, Norwegian grey elkhound, Finnish spitz, 
 40
Karelian bear dog and beagle, were under-represented in the sample. These 
breeds represented only 2% of the sample, but 21% of all the registrations.    
 
 
5.2.2 Virus neutralising antibodies in the field sample  
 
Grouping variables, the variables compared between groups and significant 
associations found in the comparisons are presented in Table 6. Significant 
differences (overall p < 0.001) in titre were detected between the unstratified 
vaccine usage groups. The dogs less than a year old had significantly lower 
titres than those aged one to two years (p = 0.01) and over two years (p < 
0.001), but the titres of dogs aged one to two years and over two years did 
not differ significantly from each other. The titres of the dogs that had been 
vaccinated once or twice were significantly lower than those of the dogs that 
had been vaccinated three or four times (p < 0.001). The mean number of 
vaccinations among the dogs less than two years of age differed significantly 
between the vaccine usage groups (p < 0.001). Mixed high and low groups 
had the most vaccinations (mean 2.8), followed by groups vaccinated with 
Dohyvac® (2.6), Canlan® (2.1), Candur®  (2.0), Nobivac® (1.2) and 
Duramune® (1.0). Overall, there were significant differences in mean age 
among three age groupings (p < 0.001), with the dogs vaccinated with mixed 
low and high vaccines being the oldest, and the dogs vaccinated with 
Candur® , Canlan®, Dohyvac®, Nobivac® and Duramune® being successively 
younger.  
 
Table 7  Proportion of dogs under 2 years of age with a detectable antibody titre 
according to their immunogenicity group and the number of vaccinations they received 
(III). Immunogenicity groups as in Table 6. 
 
        Number of vaccinations      
  1 2 3  4 
 
Immunogenicity 
group   %  (n)   %  (n)   %  (n)    %  (n) 
        
 Single high  90  (257) 99  (283) 97  (78)  100  (3) 
 Single low  39  (183) 47  (658) 61  (775)  78  (94) 
 Mixed high  - 93  (162) 97  (181)  98  (61) 
 Mixed low  - 62  (113) 74  (163)    63  (40) 
                    
 (n) is the number of dogs in each group       
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Both the number of vaccinations and age were associated with the titre and 
vaccine usage group. To control for possible confounding factors, the 
comparison of titres among vaccine usage groups was adjusted by 
classifying according to the number of vaccinations (one to four) and the age 
group (1, 2 and 3). The proportions of dogs with detectable titres in the 
different immunogenicity groups, grouped by the number of vaccinations, are 
presented in Table 7. The same division of single vaccines into low- and 
high-take vaccines was observed, irrespective of the number of vaccinations 
the dogs had received (p < 0.001 in each case). Similarly, consistent 
differences in the take were observed between the mixed low- and mixed 
high-take groups. The log10 reciprocal geometric mean titres with standard 
deviations for the age-specific immunogenicity groups are illustrated in 
Figure 7, and the proportions of dogs with detectable antibody titres in these 
groups are presented in Figure 8. 
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Figure 7  The log10 reciprocal geometric mean titres in age-specific immunogenicity 
groups in the seroprevalence study (III). Bars represent the respective standard 
deviations.  Grouping as in Table 6.  
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Figure 8  Proportions of dogs with a detectable antibody titre in age-specific 
immunogenicity groups in the seroprevalence study (III). Grouping as in Table 6.  
 
 
5.3 Epidemiological observations (IV and V) 
 
5.3.1. Clinical signs (IV) 
 
The clinical signs reported during the 1994-1995 outbreak were anorexia, 
conjunctivitis and fever that frequently fluctuated. Respiratory illness was 
characterised by rhinitis, tracheobronchitis and, in the most severe cases, by 
pneumonia. Gastrointestinal signs were manifested in the early stages of the 
disease by vomiting and diarrhoea, usually lasting for one to two days. In 
severe cases the animals remained depressed and anorexic for several 
weeks and suffered from serous-mucopurulent nasal and ocular discharges. 
Some dogs exhibited a reddening of the skin followed by a pustular rash. 
Hyperkeratosis of the pads and nose, and central nervous system signs were 
also observed. On rare occasions vesicles developed on the earflaps and a 
vesicular stomatitis was observed. Mortality rate was estimated at 30%. 
 
5.3.2 Confirmed CD cases (IV) 
 
Of the 3 649 samples examined between 1 January 1994 and 31 August 
1995, a total of 865 (23.7%) tested positive in the IFA. A total of 71.7% of the 
CD cases were among vaccinated dogs, 4.3% among unvaccinated dogs 
and 24% among dogs with no information on the vaccinations. Information on  
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the age of 42 dogs was lacking. Of the remaining 823 CD cases, 2% were 
among dogs less than 3 months of age, 76.7% among dogs 3-24 months of 
age and 21.3% among dogs more than 24 months of age. A complete 
vaccination history was available for only 351 of the cases aged 3-24 
months. Among these the proportion of dogs vaccinated with Dohyvac® was 
significantly higher than would have been expected from the market shares, 
around 70% through 1992-1994, on the assumption that all the vaccines had 
an equal take (p < 0.001). The number of confirmed CD cases among dogs 
from 1988-1996 and among dogs and other species from 1997-2007 are 
presented in Figure 10 and Table 8, respectively. 
 
Table 8  Laboratory-confirmed CD cases among dogs and other species versus 
samples tested from 1996-2007 in Finland (EELA and Evira). 
 
     Number of CDV positive (number tested) 
 
Year Dog Fox Mink Others Other species tested 
 1996 0 (184) 0 (27) 1 (14) 0 (3) a 
 1997 2 (84) 0 (19) 0 (5) 0 (4) a, b 
 1998 0 (45) 0 (16) 0 (10) 1 (8) c, d, e 
 1999 2 (48) 0 (17) 0 (19) 0 (9) a, f, g 
 2000 0 (40) 0 (5) 0 (2) 0 (4) a, g, h 
 2001 0 (17) 0 (9) 0 (7) 0 (3) g, h, i 
 2002 0 (18) 0 (20) 0 (14)   
 2003 2 (26) 0 (16) 0 (4)   
 2004 4 (43) 0 (10) 0 (6) 0 (1) a 
 2005 0 (43) 0 (34) 0 (6) 0 (2) a 
 2006 1 (36) 0 (11)    
 2007 8 (82) 0 (16)   0 (3) a, j 
  a    raccoon dog (Nyctereutes procyonoides)  
  b    pine marten (Martes martes)  
  c    European mink (Mustela lutreola)  
  d   ferret (Mustela putorius)   
  e    sable (Martes zibellina)   
  f    European badger (Meles meles)  
  g    arctic fox (Alopex lagopus) 
  h    wolf (Canis lupus)  
  i   wolverine (Gulo gulo)  
  j    Saimaa seal (Phoca hispida saimensis) 
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Table 9  Number of dogs registered (with the Finnish Kennel Club), total number of CD 
vaccines sold (statistics of VELL and EELA), market share of the high-take vaccines 
and calculated vaccine coverage in Finland in 1988-1996. 
 
 
Year 
Number of 
dogs 
registered 
Number of 
CD vaccines 
sold 
Market share 
of the high-
take 
vaccines % 
Vaccine     
coverage % 
 1988 33 885 74 626 31.5 49 
 1989 37 547 83 684 27.3 53 
 1990 41 669 249 263 23.7 100 
 1991 46 003 186 114 20.3 82 
 1992 46 623 229 860 13.6 96 
 1993 47 093 214 622 13.5 87 
 1994 44 950 292 437 9.9 100 
 1995 40 062 274 533 59.6 100 
 1996 35 932 201 733 75.7 83 
 
 
 
 
5.3.3 Dog demographics, vaccine coverage and herd immunity (V) 
 
The number of dogs registered, the total number of CD vaccines sold, the 
market share of the high-take vaccines and the calculated vaccine coverage 
in Finland during 1988-1996 are summarized in Table 9. The number of 
annually registered dogs increased rapidly from 1988 to 1991 and remained 
high until 1994. The market share of the high-take vaccine simultaneously 
decreased. The size of the registered dog population and the proportion of 
dogs less than two years of age in 1988-2006 are illustrated in Figure 9. The 
increase in the size of registered dog population and changes in the age 
structure (high proportion of young dogs) preceded the major outbreak. 
Figure 10 depicts the number of virologically-confirmed CD cases in 1990-
1996 and the HI (%) as the proportion of dogs under two years of age in 
1988-1996 with detectable levels of antibodies. Two periods with a steep 
increase in the calculated HI are apparent. Despite the fairly high vaccine 
coverage (Table 9), the HI shows a slight decreasing trend during 1990-
1994. Table 10 summarizes the market shares of the high-take vaccines in 
Finland, Oulu and Turku area and the numbers of virologically-confirmed CD 
cases in Finland, Helsinki metropolitan area, Tampere, Oulu and Turku area 
from 1990-1996. Unlike the Helsinki metropolitan and Tampere areas, a 
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high-take vaccine was the market leader in Oulu and Turku, except in 1994. 
The number of confirmed CD cases among dogs per county in Finland from 
1990-1996 is shown in Table 11. 
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Figure 9  The size of the registered dog population and the proportion of dogs under 2 
years of age from 1985-2006 in Finland. 
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Figure 10  Number of confirmed canine distemper cases and calculated herd immunity 
(%) among dogs under 2 years of age from 1988-1996 in Finland. 
 
 
 
Table 10  Market share (MS) of the high-take canine distemper vaccines (HTV) in 
Finland, Helsinki metropolitan (HMA), Tampere, Oulu and Turku areas and confirmed 
cases per area over 1990-1996 (EELA, personal communications T. Illukka, J. Rasi 
and I. Rastas, Turku, K. Wickström and R. Väyrynen, Oulu). 
 
Year 
Overall 
MS of 
HTV %  
Total no 
of CD 
cases 
CD in 
HMA 
CD in 
Tampere
MS of 
HTV in 
Oulu % 
CD in 
Oulu 
MS of 
HTV in 
Turku % 
CD in 
Turku 
1990 23.7 87 40 3 69.8 0 Ma 0 
1991 20.3 36 19 0 86.6 0 M 1 
1992 13.6 152 60 27 90.4 2 M 5 
1993 13.5 45 6 0 50.1 0 M 0 
1994 9.9 583 304 48 13.4 0 41.1 7 
1995 59.6 318 62 54 67.1 2 95.1 7 
1996 75.7 0 0 0 98.8 0 98.6 0 
a missing information       
 47
Table 11  Numbers of confirmed canine distemper cases per county from 1990-1996 in 
Finland. Helsinki Metropolitan Area abbreviated as HMA. 
 
      Year         
County (major city) 1990 1991 1992 1993 1994 1995 
Cumulative 
no of cases 
Uudenmaan (HMA) 52 26 69 10 330 79 566 
Turun ja Porin (Turku) 7 1 7 1 24 19 59 
Hämeen (Tampere, Lahti) 6 0 42 2 61 108 219 
Kymen 6 0 11 21 38 30 106 
Vaasan 1 0 6 2 5 12 26 
Keski-Suomen 
(Jyväskylä) 
2 0 0 1 62 23 88 
Mikkelin 0 0 0 0 13 5 18 
Kuopion 0 0 1 0 3 11 15 
Pohjois-Karjalan 4 1 1 0 3 2 11 
Oulun (Oulu) 0 0 3 0 4 8 15 
Lapin 0 0 0 0 1 0 1 
Ahvenanmaa 1 0 0 0 0 0 1 
Unknown 8 7 12 7 32 23 89 
Total 87 35 152 44 576 320 1214 
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6. DISCUSSION 
 
 
The overall main theme of the present thesis is the takes of canine distemper 
vaccines, both from the standpoint of seroconversion (I, II), seroprevalence 
(III) and the endemic and epidemic occurrence of CD in Finland in the 1990s 
(IV, V). The discussion is organised into corresponding sections; both deal at 
length with the reliability or biological significance of the results and 
observations. 
 
6.1 Experimental and field takes of the vaccines 
 
6.1.1 Takes of the vaccines 
 
The qualitative presence or absence of antibodies after vaccination is 
actually more important than the exact quantity, when present. The presence 
of antibodies after vaccination indicates an active immune response and 
memory. The considerably varying takes of the distemper vaccines are 
documented in detail both in experimental settings (I, II) and in the field (III, 
IV,V). An attempt to account for the varying takes is divided into finding 
associations between i) the vaccine-specific data (Tables 3 and 4) and ii) 
host- and usage-dependent data (II, III), and the respective takes. 
 
Vaccine-specific data 
The formulations of the studied vaccines are different: All CD vaccines for 
dogs are multivalent, containing one to three other antigens and sometimes 
an adjuvant in addition to CDV, whereas mink distemper vaccines contain a 
single antigen without an adjuvant (Tables 3 and 4). Several of the tabulated 
factors may have a non-spurious association with the take.  
 
The most obvious cause for the differing takes among the CD vaccines is the 
vaccine strain. In general, Onderstepoort strains are less immunogenic than 
Rockborn strains (Appel 1987, Chappuis 1995). However, one of the three 
vaccines in the high-take group, namely Nobivac®, contained the 
Onderstepoort strain and performed as well as Duramune®, which contained 
the Rockborn-type strain. Due to the fairly small sample sizes of dogs 
vaccinated with Nobivac® (n = 158) and especially Duramune® (n = 31), and 
the fact that all samples were from dogs vaccinated once and very recently, 
the performance of these vaccines may appear better than it actually is. A 
marked difference was shown between the two low-take vaccines, Canlan® 
and Dohyvac®, in the proportion of dogs with detectable antibody levels both 
in the seroconversion and field studies among dogs less than 2 years of age. 
The efficacy of an ML vaccine is dependent on the vaccine strain’s ability to  
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replicate in a host. Therefore, the method of antigen production, i.e. the cell 
line in which the vaccine strain is produced, inevitably influences the take of 
a vaccine. The antigen for Candur®  and Duramune® vaccines was produced 
in primary and continuous dog kidney cells, for Nobivac® and Canlan® in 
Vero cells and for Dohyvac® in chicken embryos. The vaccines are in the 
order of successively decreasing take and it appears that the further the 
production cell line is phylogenetically from the dog, the lower is the take. 
 
The titre of an antigen in a vaccine dose contributes to the take of the 
vaccine, provided that the vaccine strain is able to replicate sufficiently in the 
host. One of the first steps in vaccine development is to establish the dose-
response relationship (Dessmetre and Martinoid 1997). In the case of ML 
vaccines, a balance between efficacy and safety must be sought. The 
minimum and maximum titre of an antigen in a dose at release must be 
determined to confirm efficacy and safety throughout the shelf-life of a 
vaccine. Although the minimum titres of CDV antigen in a dose are not 
directly comparable among vaccines, Dohyvac® seems to have the lowest 
titre of antigen per dose. An unexpected observation concerning the group of 
dogs vaccinated with low-take vaccines (III) suggests that the dose-response 
relationship for these vaccines has not been properly established. A 
sufficiently immunogenic vaccine would be expected to induce levels of VN 
titres that would approximately follow a normal distribution curve. This was, 
for example, the case in dogs less than one year old vaccinated with 
Candur®  (vaccine 1). However, 54% of the dogs of the same age group 
vaccinated with Dohyvac® had no detectable antibodies, although when titres 
were detectable their distribution followed that of Candur®  with a lower level, 
giving a satisfactory geometric mean titre of 134. A similar result was 
obtained with Canlan® (vaccine 2). This observation can also be seen in the 
results of study I.  
 
The take of a vaccine antigen may also be influenced by other ML or 
inactivated antigens and the inclusion of an adjuvant in the vaccine. This 
should already be taken into account when a multiple vaccine is in the 
developmental stage, and will not be further discussed here. The 
administration of other vaccines, for example rabies vaccine, simultaneously 
with the CD vaccine may affect the take.  
 
Host- and usage-dependent factors (I, II, III) 
In addition to the vaccines themselves, the host animal and the number of 
vaccinations may have an impact on the take. The factors actually 
contributing, which will be discussed here, are individual variation, age, 
breed, the number of vaccinations and the animal species.  
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No vaccine will induce VN antibodies in every vaccinee. Some individuals 
are non-responders in which even several vaccinations with a high-take 
vaccine do not induce VN antibodies. The proportion of these individuals has 
been estimated to be 1% (Schultz 2006). The present data (III) are 
consistent with this: 9 out of 418 dogs (2%) vaccinated with Candur® at least 
twice were non-responders. However, a vaccine non-responder may 
seroconvert after clinical CD, i.e. exposure to a wild CDV (unpublished 
observation). In the case of low-take vaccines, the reason for the high 
proportion of animals with no detectable VN antibody could be due to 
efficient non-specific defence mechanisms that prevent the replication of a 
vaccine strain in a host early enough so that no specific response occurs. A 
specific response will then only be seen in individuals that fail to prevent 
virus replication by non-specific defence. This highlights the importance of 
properly establishing the previously-discussed dose-response relationship. In 
studies I and II, any concurrent infection at the time of vaccination would 
have been expected to influence all groups evenly. No health problems were 
observed during these studies. However, in field conditions an unknown 
number of factors contributes to the take of a vaccine. 
 
Age will influence the immune system both early and late in life, and can 
therefore be expected to influence the take of a vaccine. The immune system 
of a young animal may not function as efficiently as that of an adult 
individual. During ageing, both cellular and humoral immune responses will 
be impaired (Gerber and Brown 1974, Schultz 1982). Furthermore, during 
the first weeks or months, maternal antibodies protect newborn animals 
against infectious diseases and may interfere with ML vaccines, thus 
preventing the stimulation of active immunity. When the takes of vaccines 
are assessed in relation to age (Fig. 8), takes can be observed to differ 
among the age groups of animals vaccinated with low-take vaccines. The 
higher take among dogs over 2 years of age compared to younger dogs in 
low-take groups may in fact be explained by the booster effect of wild CDV. 
The booster effect is difficult to resolve in dogs that already have high 
enough VN titres (Prydie 1966). High VN titres are able to prevent the 
replication of CDV (wild or vaccine strain) and therefore the immune system 
will not be stimulated. Interference by maternal antibodies is considered to 
be the most important cause of vaccine failure (Fig. 4). None of the beagle 
puppies had detectable antibodies at first vaccination at the age of 12 weeks 
(I). A total of 1.7% and 2.5% of mink (13 weeks) and silver fox (16 and 14 
weeks), respectively, sampled at the time of vaccination had low antibody 
levels, but nevertheless seroconverted by 1.5–2 months after vaccination (II). 
Based on these results and current vaccination recommendations, which for 
both dogs and fur animals are designed to minimize this interference, we 
conclude that maternal antibodies are perhaps a less important cause of 
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vaccine failure than claimed. Furthermore, they can interfere with 
vaccinations only during the first weeks or months of life. 
 
Intensive breeding has led to the accumulation of several inherited diseases 
among dog breeds. Breeding of inherited immunodeficiencies has probably 
also occurred. The breed of a dog may therefore contribute to the differences 
in vaccine take. A possible breed effect was controlled in I by using pure-
bred beagle dogs. On the other hand, the breed effect was diluted due to the 
presence of several breeds in all groups of vaccinees (III). To reliably assess 
the breed effect on vaccine take, a representative sample of pure-bred dogs 
of various breeds vaccinated with a single high-take vaccine would be 
needed. 
 
The number of vaccinations had a clear effect on the take only in a single 
low-take group (Table 7). The low-take of a vaccine was not adequately 
compensated for by increasing the number of vaccinations or by using 
several vaccines if all the vaccines were of low-take. Furthermore, the 
protection provided by vaccination should be attained as soon as possible, 
ideally after one or two vaccinations. All fur animals were vaccinated only 
once, which is usually the case in the field. The majority of fur farms do not 
routinely vaccinate against CD. Emergency vaccination is employed 
immediately after the detection of CD on a fur farm or when the risk of CD 
spread from dogs to fur farms is recognised. 
 
As expected, all mink distemper vaccines performed satisfactorily in the 
target species (II). However, an equal performance in other fur animal 
species cannot be taken for granted. This may, in addition to other factors, 
explain the apparently variable results among vaccine brands and fur animal 
species during the 1985-1987 outbreak in Finland (Loikala and Kangas 
1988). The geometric mean titre induced in raccoon dog both by Distemink® 
and Distem®-R-TC vaccines was higher than that in the target species. With 
raccoon dog, antibody titres higher than with other fur animal species have 
also been observed against parvovirus (Neuvonen et al. 1982).   
 
6.1.2 Reliability of the vaccine take results 
 
It is inevitable that groups of experimental animals form clusters. This must 
be taken into account either in the design of the experiment or when 
analysing the results. In the present case the beagle dogs (I) originating from 
15 litters were divided into three groups of 25 animals and puppies 
originating from the same litter were vaccinated with a same vaccine. This 
clustering was ignored in the experimental design. While the fur animals of 
publication II were housed in separate cages, these were adjacent on two 
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sides to neighbouring cages. Furthermore, the cages in the same shedhouse 
shared for example feeding appliances. Even in the field material of 
publication III, clusters most likely occurred in the form of kennels and the 
clientele of large veterinary clinics. A non-trivial analysis of the dependence 
of any variable on the independent factors of the experimental design should 
accommodate clustering effects. This was not done in publications I or II. 
The results are, nevertheless, sufficiently reliable because analysis of 
clustering is considered effective in taking into account the systematic 
differences in, for example, the genetic, climatic, management or veterinary 
service factors. All of these were generally constant in the experimental 
designs. The clustering in publication III may have had an impact on the 
results; however, the associated data were too limited to permit multilevel 
analysis. The possible clustering effects are considered to be offset at least 
to some extent by the comparably large sample of dogs (n = 4 627) from 
around the country. 
 
All three CD vaccines and two of the mink distemper vaccines were 
commercial products, registered in Finland (Tables 3 and 4). The third mink 
distemper vaccine was intended to be used in mink and ferret, but not 
registered in Finland. It is reasonable to assume that although only one 
batch of each vaccine brand was used in the experiments (I and II), batch-to-
batch variation was within acceptable limits, and therefore the results of the 
seroconversion studies are representative of each brand of the triple dog 
vaccines or mink distemper vaccines. In the field, several batches of the 
three CD vaccine brands were used. Although various combinations of 
vaccines were available for dogs, triple vaccines containing CDV, CAV-1 or -
2 and CPV as antigens were the most popular combinations. Moreover, 
besides the multitude of other factors, the circulation of a wild CDV in the 
population probably contributed to the observed take of each vaccine, 
especially among the older age groups.  
 
The field sample (III) is considered to represent the vaccinated urban dog 
population, firstly because it is relatively large (approximately 10% of the 
dogs registered annually in Finland), secondly because the use of the three 
main vaccines (Candur® , Canlan® and Dohyvac®) in the sample 
corresponded with the contemporary sales proportions, and thirdly because 
the breed distribution in the sample accorded with the registration statistics 
of the Finnish Kennel Club. 
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6.2 Occurrence of CD from 1988-2007 in Finland 
 
CD in dogs reappeared in 1990, after 16 years of absence. Three periods 
can be distinguished: endemic occurrence from 1990-1993, epidemic 
occurrence from 1994-1995 and sporadic occurrence from 1996 onwards. 
The endemic situation is described in publication V and the epidemic episode 
in both publications IV and V. In both articles, and especially in V, the 
combined impact of vaccination coverage and the takes of the vaccines (in 
terms of herd immunity) on the proliferation of CD is described in extensive 
detail. An attempt to extend the explanation for the rise and fall in the 
epidemic, given especially in V, is presented. The situation after 1996 is also 
briefly reviewed. 
 
Clinical signs reported during the major outbreak were typical for CD (IV). In 
a case-control study conducted after the reintroduction of CD in 1990 (Forell 
1993, unpublished observation), neurological and integumentary signs were 
present in 54% and 6% of the cases, respectively, and the case-fatality rate 
was reported to be 30%. A high prevalence of neurological signs was also 
observed by Järvinen et al. (1990). During the major outbreak from 1994-
1995, neurological and integumentary signs were reported in 7.5% and 
45.5% of confirmed cases, respectively (Lounela et al. 1997). Since 
neurological signs are the major determinant of the prognosis and recovery 
from CD, the reported mortality rate of 30% during the major outbreak may 
be an overestimate.   
 
6.2.1 Endemic and epidemic occurrence of CD from 1990-1995 
 
After the appearance of sylvatic rabies in 1988 in Finland, a six-month 
quarantine for imported dogs was abandoned. Only rabies vaccination was 
obligatory for dogs before entering the country. This increased both the 
imports of dogs and the number of Finns travelling with their dogs abroad. 
Since the majority of the imported dogs are puppies, it is not surprising that 
CD was reintroduced to the country. Indeed, the first two confirmed cases 
were detected in imported puppies in March 1990 (Järvinen et al. 1990). In 
spite of the severe economical recession at the beginning of the 1990s and 
the high rate of unemployment (over half a million unemployed persons), 
travelling and imports of dogs further increased when the Soviet Union 
collapsed and Estonia regained independence in 1991, and the previously 
practically closed borders to the East and South were opened.   
 
The size of the Finnish dog population increased by roughly 100 000 dogs 
from 1990-1995, and allowing for the proportion of non-registered dogs, was 
estimated by the Finnish Kennel Club to be half a million. According to 
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registrations, the proportion of dogs less than 2 years of age remained above 
20% through 1988-1994 (Fig. 9). The size of the registered dog population in 
1990 alone exceeded 300 000, which is considered as the minimum 
population size required to sustain a morbillivirus in circulation in the 
absence of vaccinations (Black 1991).  
 
CD has probably been introduced to Finland several times since 1990. The 
symptoms observed after the introduction in 1990 and during 1994-1995 
differed with respect to the neurological signs, which may suggest 
differences in virulence among circulating CDV strains. The high incidence of 
neurological signs after the reintroduction of CDV could also be a reflection 
of the poor herd immunity (Böhm et al. 1989). However, only two isolates of 
CDV from 1994 exist, which prevents, for example, sequence-level 
comparisons (Ek-Kommonen et al. 2003b). Furthermore, the strain 
responsible for the epidemic was at least antigenically close enough to the 
vaccine strains to enable effective prophylaxis. 
 
An independent estimate for the critical level of HI could be calculated using 
the so-called basic reproduction ratio, R0 (Nokes and Anderson 1988b). For 
measles and phocine distemper, an R0 from 11 – 18 and 2-3 has been 
estimated, respectively (Woolhouse and Bundy 1997, Swinton et al. 1998). 
Unfortunately, no numerical estimates for the R0 of CD have been presented. 
However, R0 is very sensitive to heterogeneities created by the spatial 
structure of populations (Dobson and Foufopoulos 2001), by the age and 
contact structures in populations, and by a variety of ill-defined management 
and behavioural factors. A critical level based on R0 would therefore have to 
be interpreted with extensive provisions.  
  
Two periods with a steep increase in the HI were apparent (Fig. 10). The 
first, during 1990, is attributed to the tripling of vaccine sales after re-
introduction of CD, and the subsequent increase in vaccine coverage from 
around 50% to 100% (Table 9). In spite of the steep improvement in HI, CD 
remained at a low endemic level in the dog population. The second increase 
in the HI was due to the withdrawal of the low-take vaccine, which had 
market share of 74%, and the subsequent increase in the market share of 
high-take vaccines in 1995. When the takes of the vaccines differ 
significantly, the market share of each vaccine determines the level of HI 
achieved. This is clear when HI is compared between the years 1990, 1994 
and 1995, which all had a vaccine coverage of 100%.   
 
No exact information on the dog population density exists, but it is assumed 
that there is a fairly constant ratio between the numbers of dogs and the 
numbers of people. The CD cases appeared to accumulate in the Helsinki 
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metropolitan area and in some of the biggest cities in the southern and 
central parts of the country (Table 11). However, there was marked spatial 
heterogeneity. In the following calculation of the normalized numbers of CD 
cases per 100 000 citizens, the census figures from 1994 (Ministry of 
Interior) and the average number of CD cases from 1994-1995 were used. 
Thus, the normalized numbers were 28.5 in Tampere, 4.3 in Turku, 0.9 in 
Oulu, 23.2 in Lahti and 39.7 in Jyväskylä (Table 10). Turku and Oulu 
appeared to form pockets of resistance, especially when compared to the 
normalized number of 17.3 for the whole country. This can to a large extent 
be attributed to the substantially higher percentages of high-take vaccines 
used in these cities than elsewhere in the country (personal communications, 
R. Väyrynen and K. Wickström, Oulu; T. Illukka, J. Rasi and I. Rastas, Turku; 
statistics of EELA).  
 
The number of CD cases reflects the area-specific infectious pressure, which 
can be considered as inverse to the level of herd immunity. The infectious 
pressure and the number of cases form a kind of vicious cycle: the higher the 
pressure, the higher the number of cases. When the pressure is low, as for 
example in the province of Oulu (Table 11), even low-take vaccines can help 
to keep the disease in check (or at least appear to do so). However, in 
situations of high infectious pressure only vaccines that induce solid 
immunity are able to break the cycle. Of course, immunity due to natural 
infection eventually contributes to the increase in the HI. The observed 
heterogeneity in the numbers of cases, translated to variability in herd 
immunity, can on the other hand also lead to pockets of susceptibility and an 
increased overall risk of infection, as described in the case of measles by 
van den Hof et al. (2002) and Glass et al. (2004). 
 
Vaccine-induced HI among production animals, such as fur animals, is often 
a result of the use of a single vaccine brand on a farm, on several farms or 
even over much larger areas. In the dog population, several vaccine brands 
normally contribute to HI. The poor performance of one vaccine brand is 
easily compensated by the protection achieved with better-performing 
vaccines, at least when none of the brands dominates the market. This, 
unfortunately, was not the case with the low-take vaccines, and especially 
the Dohyvac® brand, in the 1990s in Finland. According to Rockborn and 
Klingeborn (1996), Dohyvac® also enjoyed a market share of 70% in 
Sweden, and the observed take of the vaccine in Sweden agreed well with 
the take in Finland (Olson et al. 1997a). In Sweden, CD occurred 
sporadically from 1986-1996; zero to six cases were reported annually. 
However, imports of dogs were strictly regulated and, unlike in Finland, 
canine distemper vaccinations were a condition for import (Olson et al. 
1996b). 
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To conclude: several factors contributed to the reoccurrence of CD in 
Finland, which culminated in a major outbreak in 1994-1995. Firstly, lifting of 
the six-month quarantine on imported dogs in the late 1980s severely 
increased the infectious pressure of CD. Secondly, the size of the dog 
population, and therefore according to registrations the proportion of young 
dogs, which are known to be at highest risk of contracting CD, increased 
rapidly. Thirdly, the HI decreased steadily from 65 to 52% among young 
dogs between 1990 and in the end of 1993, leading to a situation in which a 
large proportion of young dogs, despite the fairly high vaccine coverage, 
remained unprotected.    
 
6.2.2 Reliability of the epidemiological data 
 
Confirmed diagnosis of CD   
The representativeness of the sampled CD cases, i.e. how well they 
represented all diseased dogs during the major outbreak, is a critical issue 
when making inferences about the actual impact of different vaccines on the 
situation. Sampling bias may partly explain the obviously low percentage of 
unvaccinated dogs (4%) compared to that of vaccinated dogs (72%). It may 
well result from the fact that clinicians considered laboratory confirmation of 
CD diagnosis unnecessary in the case of unvaccinated dogs, or a reluctance 
among owners to pay for further testing. The rest, almost one fourth of the 
cases, had an obscure vaccination history.  
 
Only 24% of all the samples tested by IFA were positive during 1994-1995. 
In another study, 42% of the cases tested positive with the same method, 
whereas 74% had IgM antibodies to the virus (Blixenkrone-Møller et al. 
1993). The sensitivity of IFA depends on both the quality of the sample and 
the timing of sampling. It is not possible to detect the virus with IFA if a 
sample is taken too late in the course of the infection. However, the annual 
proportions of confirmed cases from 1990-1996 should be comparable and 
reflect the situation satisfactorily, provided that sampling is carried out at the 
same frequency among clinically suspected cases from year to year. In 
general, after the introduction of a disease there will first be underdiagnosis 
and later overdiagnosis, especially if diagnosis is only based on clinical 
signs.  This is probably reflected in the sampling frequency over the period. 
 
No difference related to vaccine usage was observed among confirmed CD 
cases from 1990-1993. However, the number of cases was small and 
information on vaccinations scarce. The significantly higher proportion of 
Dohyvac®-vaccinated dogs among the cases from 1994-1995 may be 
attributed to several factors: 1) sampling bias towards vaccinated dogs, 2) 
the presence of the majority of cases in the Helsinki metropolitan area,
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where Dohyvac® was widely used, 3) the large clinics situated in areas with 
high infectious pressure, 4) the possibly greater willingness of large clinics to 
take samples. Any outbreak also involves vaccinated individuals: the higher 
the infectious pressure the higher the number of cases among vaccinees. 
Although the observation of a significantly higher proportion of Dohyvac®-
vaccinated dogs among the diseased can not be blindly relied upon, 
evidence from the low-take of Dohyvac® (III) and the low incidence of cases 
in geographical areas  where high-take vaccines were market leaders (V), 
both suggest that this observation is tenable. 
 
Data used to calculate the size and structure of the dog population, 
vaccine coverage and HI  
Vaccine coverage was calculated by using the sales statistics of the CD 
vaccine brands and the annual number of registered dogs, and by taking into 
account the current CD vaccination recommendations. The official sales 
statistics are comprehensive and accurate up to 1996, because all animal 
vaccines were distributed via EELA. The numbers of registered dogs 
obtained from the Finnish Kennel Club are also considered accurate. Two 
estimates, the proportion of non-registered dogs and the life-expectancy of 
ten years for each dog, were used to calculate the size of the total dog 
population, which contributed to the number of vaccines needed annually. 
The local estimate for a life-expectancy of ten years is supported by British 
and German surveys, where average ages were 11 years 1 month and 10 
years, respectively (Michell 1999, Eichelberg and Seine 1996). Both the 
registered and non-registered dogs were assumed to be similarly vaccinated. 
The only available information supporting this assumption came from study 
III, which showed that mixed-breed (non-registered) dogs in the field sample 
tend to be vaccinated largely in the same manner as pure-bred dogs. 
However, the vaccine coverage calculated here is in fact a best-case 
scenario, i.e. it shows what could have been achieved with the ideal 
distribution of vaccines. Because the immunity against CD achieved by ML 
vaccines is known to last for years (Olson et al. 1997b, Schultz 2006), in our 
calculation each dog was assumed to be vaccinated six times during its ten-
year life. In reality, vaccinations tend to accumulate in the same individuals, 
and therefore the number of vaccines used is not a direct measure of the 
coverage.  
 
6.2.3 Sporadic occurrence of CD from 1996 – 2007 
 
Only sporadic cases of CD among dogs have been observed since 1995 
(Table 7). Practically all confirmed cases have been associated with imports 
of dogs, and the continuous low infectious pressure is caused by these 
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imports. The pattern of occurrence of CD in Finland during the last ten years 
has resembled that in Sweden from 1985-1996. IFA has mainly been used to 
confirm clinical CD diagnoses, but the use of RT-PCR methods is increasing 
due to their higher sensitivity and other advantages. As illustrated in Figure 
9, Finland is in the middle of a `puppy boom´ with young dogs making up 
over 20% of the registered population. Based on our earlier experience, this 
can be regarded as a high risk period with respect to CD. However, with the 
currently-available vaccines (Nobivac® and Duramune®) and assuming 100% 
vaccine coverage, a herd immunity of around 90% should be attainable 
regardless of their relative market shares. If the average take of the available 
vaccines is a non-exacting 80%, the above-mentioned critical level 
corresponds to a vaccine coverage of some 94%. This is consistent with the 
90-95% vaccine coverage needed to control measles (Nokes and Anderson 
1988a).
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7. CONCLUSIONS 
 
 
1. The development of vaccine-induced immunity in an individual is a 
multifactorial process, partly depending on the properties of the 
vaccine but also, and especially in the case of low-take vaccines, on 
host-specific factors such as age, animal species and breed, and on 
other factors having an influence at the time of vaccination. 
 
2. The development of vaccine-induced immunity in a population, i.e. 
herd immunity, depends on the process occurring in individuals; 
however, while prevention of the clinical manifestation of the disease 
is sufficient on the individual level, on the population level it is crucial 
to halt the circulation of the virus. To achieve this, the proportion of 
individuals with sufficient immunity should be maximized, which 
imposes higher demands on the performance of vaccines than the 
mere prevention of clinical signs. 
 
3. The ultimate test and criterion for a vaccine is its contribution to herd 
immunity. This was clearly demonstrated in the course of the 
occurrence of canine distemper in Finland in the 1990s. 
 
4. The spatial heterogeneity in the population and vaccine usage may 
have been a more definitive factor in the epidemiology of canine 
distemper in Finland than previously thought. 
 
5. Differences in performance among canine distemper vaccines in the 
field are often difficult to resolve without extensive associative spatial 
and other information. In Finland, low-take vaccines had a major 
contribution to the vaccine induced immunity, which made this 
resolution possible. 
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